

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/772,445  
Applicant : KLEINMAN et al.  
Filed : January 29, 2001  
TC/A.U. : 1654  
Examiner : Ronald T. Niebauer

Docket No. : 2600-109  
Customer No. : 06449  
Confirmation No. : 1045

**Declaration of Dr. Jo-David Fine Under 37 C.F.R § 1.132**

Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

I, Jo-David Fine, M.D., M.P.H., FRCP (London), declare as follows:

1. I am Professor of Medicine (Dermatology) and Pediatrics, Vanderbilt University, Nashville, Tennessee.
2. I have been awarded a Bachelor Science Degree in Chemistry from Yale College, and a M.D. degree (with distinction) from University of Kentucky College of Medicine.
3. My post graduate training included an internship in medicine and a junior assistant residency in medicine at Duke University Medical Center, a residency in Dermatology in Massachusetts General Hospital in Boston with a Clinical Fellowship at Harvard University, a Senior Residency in Dermatology at Lahey Clinic Foundation in Boston with a Clinical Fellowship at Harvard University, a Medical Staff Fellowship in Dermatology at the National Institutes of Health, National Cancer Institute, and various faculty positions at the medical schools of the University of Alabama at Birmingham, the University of North Carolina at Chapel Hill, the University of Kentucky, Vanderbilt University, and St. John's Institute of Dermatology at Guy's, King's and St. Thomas' School of Medicine (King's College London, University of London), St. Thomas' Hospital, London

and the Department of Cell & Molecular Pathology at St. John's Institute of Dermatology, London. A copy of my Curriculum Vitae is attached hereto as Exhibit A.

4. I have been informed that claims of the above-referenced U.S. patent application have been rejected on the basis of U.S. Patent No. 6,030,948 (Mann), alone, or in combination with other references.
5. I have been informed that it is the position of the U.S. Patent and Trademark Office in an Office Action dated April 17, 2008, that Mann teaches a method of applying a composition containing thymosin  $\beta 4$  "to the scalp (claim 8). Prior to application to the scalp, an acid peel (i.e., chemical peel) solution is applied to the scalp and then removed. The removal of the acid peel solution results in the removal of an outer later of skin and results in **abrasions/damage/lesions/wounds** upon the skin." (emphasis added).
6. I have studied U.S. Patent No. 6,030,948 to Mann. For the following reasons, the statement that the acid peel of Mann results in "abrasions/damage/lesions/wounds" on the skin is incorrect.
7. Column 10, lines 56-62 of the Mann patent states as follows:

*"In the method of this invention, the following steps are performed in the order noted: (1) cleansing the scalp with a cleansing agent; (2) treating the cleansed scalp with a keratin solvent system; (3) applying a topical anesthetic (optional); (4) applying an acid peel solution; (5) applying a hyperactive urea gel formula (optional) and (6) applying a hair regeneration composition."*
8. Acid peel systems are described in Step 4 of Mann, column 13, line 19 to column 14, line 11, and in claims 17 and 18 of Mann, as follows:

*"Step 4: Acid Peel Systems*

*Application of the optional fragrance-based topical anesthetic is followed*

*by the application of an acid-based system with the composition shown in Table 6. This composition included a series of physiological acids, including citric acid and pyruvic acid, in combination with a surfactant that will enhance penetration and a solubilizing system which also facilitates penetration. The acid peel system is allowed to remain on the scalp for anywhere between 1 minute to 8 hours or more. If the acid peel system is allowed to remain on the scalp for more than about 30 minutes, an occlusive cap may be placed on the head covering the scalp. As used herein, an occlusive cap means any structure, which when placed on the scalp of the head, prevents the acid peel system from leaving the surface of the scalp.*

*The following Table 10 provides a range of concentrations of ingredients that may be used in the acid peel solution.*

TABLE 10 ACID PEEL

*Citric acid 20.00 Salicylic acid 10.00 Methyl salicylate 10.00 Menthol 1.00 POLYSORBATE-80 3.00 2-Phenoxyethanol 6.00 Pyruvic acid 10.00 TERGITOL 15-S-7 1.00 Methyl nicotinate 0.50 Alcohol SD40 A (190) 23.00 Demineralized water 15.50*

*The above ingredients are shown in weight percent, and are available from commercial suppliers such as Brooks, Sigma (St. Louis, Mo.) and Aldrich (Milwaukee, Wis.)."*

9. Claims 17 and 18 of Mann read as follows:

*"17. The method of claim 8 wherein the acid peel solution comprises at least one physiological acid.*

*18. The method of claim 17 wherein the physiological acid is citric acid, ascorbic acid or pyruvic acid."*

10. Acid peels are used for the purpose of skin exfoliation. The primary use of acid peels is to help rid skin surface areas of dead cells and to stimulate cellular proliferation of a new healthy-looking, smoother, more evenly pigmented, and "glowing" skin. Mann's patent describes the use of physiological acids (specific acid peels) to increase skin permeability.
11. Claim 17 of the above referenced Mann patent indicates that the acid peel solution comprises at least one physiological acid. Claim 18 indicates that the physiological acid is citric acid, ascorbic acid, or pyruvic acid. Citric acid (a fruit acid), and ascorbic acid (capable of being extracted from fruits), are alpha hydroxyacids (AHAs). Pyruvic acid is an alpha-keto acid. These physiological

acids described in the claims are weak acids as are other naturally-occurring AHAs. AHAs are the mildest of the acid or chemical peels and are most widely used for skin exfoliation because of their effectiveness and the absence of toxicity. Other types of acid peels are the Beta-lift peels or the beta hydroxyacids (BHA). BHAs are effective in lifting the topmost layer of skin by "dissolving" the desmosomes which bind it to the underlying epidermis, triggering cell division (proliferation), skin cell production and shedding.. An example of a beta hydroxyacid used as an acid peel is salicylic acid. Salicylic acid, which is soluble in oil, can exfoliate oily skin more effectively than other acid peels. At times AHAs and BHAs are used in combination as exfoliants.

12. The physiologic acids or acid peels identified in the Mann passages quoted above, and claims 17 and 18 of Mann, act by accelerating the shedding or loosening of the topmost layers of the skin (stratum corneum or keratinized epithelium) by decreasing their cohesiveness. The most effective of the AHA peels is glycolic acid.
13. Any person skilled in this art would recognize that surface acting acid peels as disclosed in Mann do not cause "abrasion/damage/lesions/wounds" on skin, as stated in the April 17, 2008 Office Action. One cannot hurt dead cells. The acid peels that Mann describes affect the outermost portion of the epidermis or skin, which is made up primarily of about 15-20 layers of dead cells that lack nuclei. Acid peels do cause surface exfoliation by reducing cellular cohesiveness and/or by denaturing or fragmenting the cell adhesion proteins of the desmosome complex. The acid peel solution that Mann describes, as stated in the patent, increases the permeability of the skin to his hair regeneration composition, but in no way causes abrasion, damage, lesions and/or wounds on the skin.
14. All statements made herein of my own knowledge are true and all statements made on information and belief, are believed to be true. These statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



Jo-David Fine, M.D., M.P.H., FRCP

7.28.08

Date

Declaration under 37 CFR §1.131  
Application No. 09/772,445  
Page 5

1516673\_1

## Curriculum Vitae

### Jo-David Fine, M.D., M.P.H., FRCP

#### Present position and address:

Professor of Medicine (Dermatology) and Pediatrics, Vanderbilt University, Nashville, TN  
Head, National Epidermolysis Bullosa Registry, Nashville, TN

Division of Dermatology, Department of Medicine  
c/o VMG Patterson Dermatology  
1900 Patterson Street  
Suite 100  
Nashville, TN 37203  
(615) 329-0801  
fax (615) 320-7055  
e-mail: Jo-David.Fine@vanderbilt.edu; ProfMoose@aol.com

**Birthplace/Date:** Louisville, Kentucky April 9, 1950

#### Education:

J.M. Atherton High School (with honors), Louisville, Kentucky	9/65 - 6/68
Yale College. B.S., Chemistry ("Intensive Degree" Major)	9/68 - 1/72
University of Kentucky College of Medicine. M.D. (with distinction)	8/72 - 6/76
University of North Carolina at Chapel Hill, School of Public Health, M.P.H., Epidemiology	8/91 - 12/92

#### Postgraduate Training:

Duke University Medical Center, Durham, North Carolina Intern, Medicine Junior Assistant Resident, Medicine	7/76 - 6/77 7/77 - 6/78
Massachusetts General Hospital, Boston, MA., & Harvard Medical School, Resident, Dermatology (Clinical Fellow, Harvard University)	7/78 - 6/80
Lahey Clinic Foundation, Boston, MA., & Harvard Medical School, Samuel Moschella, M.D. (preceptor) Senior Resident, Dermatology (Clinical Fellow, Harvard University)	7/80 - 6/81
National Institutes of Health, National Cancer Institute, Dermatology Branch, Bethesda, MD., Stephen Katz, M.D., Ph.D. (preceptor) Medical Staff Fellow, Dermatology	7/81 - 6/83
St. John's Institute of Dermatology, at Guy's, King's and St. Thomas' School of Medicine (King's College London, University of London), St. Thomas' Hospital, London, England Visiting Professor (sabbatical), Dept. of Cell & Molecular Pathology, with Robin A.J.Eady, D.Sc. (Med.) FRCP, Dean - St. John's Institute	9/00 - 3/01

#### Academic Positions:

<u>University of Alabama at Birmingham School of Medicine</u> , Birmingham, AL.	7/1/83 - 7/1/90
Department of Dermatology Director of Dermatologic Research Assistant Professor	7/83 - 6/90 7/83 - 5/85

Associate Professor	5/85 - 6/90
UAB Comprehensive Cancer Center Associate Scientist	8/83 - 6/90
Birmingham Veterans Administration Medical Center Consultant, Dermatology Chief, Dermatology Section, Medical Service	8/83 - 12/83 1/84 - 6/90
UAB Institute of Dental Research Investigator & Co-Director, LM-EM-Histochemistry- Autoradiography Unit	9/84 - 2/88
UAB Multipurpose Arthritis Center Scientist	11/85 - 6/90
<u>University of North Carolina at Chapel Hill,</u> <u>School of Medicine,</u> Chapel Hill, NC	7/1/90 - 8/19/02
Department of Dermatology Associate Professor Professor Residency Program Director	7/90 - 8/92 9/92 - 8/02 7/00 - 1/02
Fayetteville Veterans Administration Medical Center Consultant, Dermatology	7/90 - 8/02
<u>University of North Carolina at Chapel Hill,</u> <u>School of Public Health,</u> Chapel Hill, NC	12/93- 8/02
Department of Epidemiology Adjunct Professor Clinical Professor	12/93 - 12/94 1/95 - 12/02
<u>North Carolina State University, College of Veterinary Medicine,</u> Raleigh, North Carolina	1994 - 12/02
Department of Clinical Sciences (formerly named Dept. of Companion Animal and Special Species Medicine) Adjunct Professor	Spring 94 - 12/02

St. John's Institute of Dermatology at Guy's, King's and St. Thomas' School  
of Medicine (King's College London, University of London),  
St. Thomas' Hospital, London, England

Dept. of Cell & Molecular Pathology  
Visiting Professor & Visiting Consultant in Dermatology 9/00 - 3/01

University of Kentucky College of Medicine, Lexington, KY 12/02 - 9/04

Department of Medicine  
Professor of Medicine (Dermatology) - Voluntary Faculty

Vanderbilt University School of Medicine, Nashville, TN 9/04 - present

Division of Dermatology, Department of Medicine  
Professor of Medicine (Dermatology)

Department of Pediatrics  
Professor of Pediatrics

VA Tennessee Valley Healthcare System, Nashville campus 12/04 - present  
Consultant, Dermatology

**Other Professional Positions:**

Dermatology Associates of Kentucky 9/02 - 9/04  
Dermatologist (private practice)



## **University, Hospital, & VA Committees & Administrative Roles (1983 - present):**

### University of Alabama at Birmingham, Birmingham, AL

Scientific Advisory Committee, General Clinical Research Center Research & Development Subcommittee, Oncology "A" (Human Use Panel), Birmingham VAMC	1984 - 1986
Cost Containment Committee, University of Alabama Hospital	1987 - 1988
Pharmacy and Therapeutics Committee, Univ. of AL Hospital	1987 - 1990
	1989 - 1990

### University of North Carolina at Chapel Hill, Chapel Hill, NC

#### University-wide Committees:

Faculty Council	7/93 - 6/96
Provost's Task Force on The University and Lifelong Learning	11/98 - 5/99

#### School of Medicine:

Medical School Admissions Committee member	11/90 - 6/96
Out-of-State Applicant Subcommittee	6/94 - 6/96
Reapplicant Subcommittee	8/94 - 6/96
First & Second Year Course Directors' Committee	10/95 - 2/01
Syllabus Subcommittee	1999
Second Year Curriculum Evaluation Committee	1996
Alpha Omega Alpha Gamma Chapter (UNC-CH)	
Faculty Committee (for student membership selection)	1998

#### Department of Dermatology:

Search Committee member, Wheeler Professorship in Dermatology	1991
Dermatology Residency Selection Committee	1990 - 2002
Subcommittee to Revise Second Yr Medical School Curriculum	1994 - 1995
Course Director, Second Year Medical School Dermatology Curriculum	1995 - 2001
Director, Dermatopathology Fellowship Program	1998 - 2002
Medical Student Career Goal Advisor for Dept. of Dermatology	3/00 - 8/01
Program Director, Dermatology Residency Program	7/00 - 1/02
Head, Dermatology Clinical Trials Workgroup	8/01 - 8/02

### North Carolina Memorial Hospital / UNC Hospitals:

Pharmacy & Therapeutics Committee	11/90 - 10/96
Hearing Committee (ad hoc medical staff appointment grievance-based)	7/00

### Vanderbilt University School of Medicine, Nashville, TN

#### Division of Dermatology:

Medical Director, VMG Patterson Street Dermatology Clinic	2004 - present
Dermatology Executive Committee	2/06 - present
Member, Electronic Medical Record Committee	2005
Dermatology Residency Selection Committee	2006 - present
Member, Excellence Practice Committee	10/06 - present

### **Hospital Appointments**

University of Alabama Hospitals, Birmingham, AL Attending Physician	1983 – 1990
Birmingham Veterans Administration Medical Center, Birmingham, AL (Attending Physician & Chief of Dermatology)	1983 - 1990
North Carolina Memorial Hospital & University of North Carolina Hospitals, Chapel Hill, NC (Attending Physician)	1990 – 2002
Fayetteville Veterans Administration Medical Center, Fayetteville, NC (Dermatology Consultant)	1990 – 2002
University of Kentucky Medical Center, Lexington, KY (Voluntary Faculty)	2002 – 2004
Saint Joseph HealthCare, Lexington, KY (Courtesy Staff) St. Joseph Hospital St. Joseph East Hospital	2002 – 2004
Central Baptist Hospital, Lexington, KY Courtesy Staff	2002 – 2004
Samaritan Hospital, Lexington, KY Active Staff	2002 – 2004
Cardinal Hill Hospital, Lexington, KY Consulting Staff	2002 – 2004
Meadowview Regional Medical Center, Maysville, KY Courtesy Staff	2002 – 2004
Georgetown Community Hospital, Georgetown, KY Courtesy Staff	2002 - 2004
Frankfort Regional Medical Center, Frankfort, KY Consulting Staff	2003 - 2004
Continuing Care, Lexington, KY (Active Staff)	2003 - 2004
Select Specialty Hospital, Lexington, KY (Active Staff)	2003 - 2004
Vanderbilt University Medical Center, Nashville, TN Attending Physician	2004 - present
VA Tennessee Valley Healthcare System, Nashville campus Attending Physician (WOC)	2005 - present

#### Academic Awards (Undergraduate):

National Science Foundation Undergraduate Summer Research Fellowship (Yale University, Dept. of Chemistry)	1971
---	------

#### Academic Awards (Medical School):

Alpha Omega Alpha	1975
Department of Medicine Prize (highest class standing in Internal Medicine)	1976
Upjohn Achievement Award (overall highest class standing, clinical years)	1976
Student Research Award, First Place (first ever awarded to a freshman)	1973
NIGMS Medical Scientist Research Fellowship (1-F12-GM-56, 064-01) for M.D.-Ph.D. in Biochemistry (first one approved for the Univ. of Kentucky but eventually not funded due to Nixon's massive FY 1974 budgetary cutbacks)	1973
Graduated with honors (with only 7 other medical students)	1976

#### Other Professional Awards or Recognitions:

##### Honorary fellowships or society memberships:

Fellowship, American College of Physicians	1984
Membership, Southern Society for Clinical Investigation	1988
Membership, American Dermatological Association	1996
Fellowship, Royal College of Physicians (London)	2007

##### Other professional awards:

Distinguished Service Award, Dystrophic Epidermolysis Bullosa Research Association of America	1984
New Investigator Research Award (R23), NIH / NIAMS	1985 - 1988
Midcareer Investigator Award for Patient-Oriented Research (K24), NIH / NIAMS (first one to be awarded in the field of Dermatology)	1999 - 2004 *

\* returned to NIH in August 2002, due to career change

Gold Triangle Award, American Academy of Dermatology	
Lifetime Achievement Award for contributions to the field of epidermolysis bullosa	July 2005
Honorary Life Membership, Dystrophic Epidermolysis Bullosa Research Association of the United Kingdom / International (only the 2nd one awarded; 1st to an American)	December 2006

##### Teaching awards or recognitions:

Course director of highest rated specialty-based course within the 2nd Yr Medical School Curriculum (Univ. of North Carolina)	Spring 1996
Sophomore Basic Science Teaching Award (UNC School of Medicine) (Highest individual faculty teaching award given during the pre-clinical years)	August 1998
Teaching Excellence Award (UNC School of Medicine)	August 2000

##### Citation impact:

First author most often cited in the dermatological literature, 1982-1996  
(per a 1998 impact study prepared by the editors of the [Archives of Dermatology](#)):

Stern RS & Arndt KA: Top cited authors in Dermatology. A citation  
study from 24 journals, 1982-1996. [Arch Dermatol](#) 135: 299-302, 1999.

also cited in Stern RS & Arndt KA: Classic and near-classic articles in the dermatologic literature. Arch Dermatol 135: 948-950, 1999.

One of the articles first authored in 1991 (J Am Acad Dermatol 24: 119-135, 1991) was the sixth most cited article in this journal from 1979 (founding issue) - 1995.

One of the articles first authored in 2000 (J Am Acad Dermatol 42: 1051-1066, 2000) was the most highly cited JAAD article during a 2.5 year citation window (2001 - mid 2003) (per Wiss K: The JAAD top ten list. J Am Acad Dermatol 52: 166-164, 2005)

**Medical Specialty Board Status:**

National Board of Medical Examiners	Diplomate 1977
American Board of Internal Medicine	Diplomate 1980
American Board of Dermatology	Diplomate 1981
Board sub-certification in Dermatological Immunology / Diagnostic and Laboratory Immunology	Diplomate 1985

**Visiting Professorships and Major or Named Invited Lectureships:**

1984	Visiting Professor	Tulane University
1985	Visiting Professor	Vanderbilt University
1986	Visiting Professor	Emory University
1987	Visiting Professor Guest Lecturer	State University of New York, Buffalo Harvard Medical School, Mass. General Hospital & Beth Israel Hospital
1988	<b>Howard Fox Lecturer</b>	New York University
1989	Visiting Professor Visiting Professor Guest Lecturer Guest Lecturer	Brown University Harvard Medical School, Mass. General Hospital & Beth Israel Hospital St. John's Institute of Dermatology, London Imperial Cancer Research Fund, London
1990	Visiting Professor	Penn State University
1991	Guest Lecturer Distinguished Guest Lecturer	University of Tennessee, Memphis Wilford Hall USAF Medical Center
1992	Guest Lecturer Visiting Professor	Medical College of Virginia Univ TX Medical Branch, Galveston
1993	<b>Julius Stone ADSA Lecturer</b>	Hawaii Dermatology Symposium
1994	Visiting Professor Grand Rounds (Peds) Grand Rounds (Derm)	Northwestern University Univ. of Minnesota Univ. of Minnesota
1995	<b>First Robert Jackson Lecturer</b>	University of Ottawa, Canada
1996	Guest Professor	University of South Florida
1998	Visiting Lecturer Visiting Professor	University of Florida St. John's Institute of Dermatology, London
2000	Guest Lecturer Guest Lecturer Visiting Professor (6 mo.) Guest Lecturer	Univ. of Sao Paulo, Brazil Medical College of Georgia St. John's Institute of Dermatology, London Imperial Cancer Research Fund, London
2001	Guest Lecturer Guest Lecturer	Univ. of Edinburgh, Scotland Guy's Hospital, London

2002	Guest Lecturer	Univ. of Texas at Houston
	Proctor & Gamble	University of Cincinnati
	Lecturer	
	Visiting Professor	Brown University
	Guest Lecturer	Duke University
	10th Bernice Fine	University of Louisville
	Memorial Lecturer in	
	Cutaneous Medicine	
2003	Invited Speaker	Ohio State University
2004	Visiting Professor	Henry Ford Hospital
	Guest lecturer	Kansas University Medical Center
2005	Invited overseas speaker	The Royal Society (London)
2006	Visiting Professor	Paracelsus Private Medical University, Salzburg
	Visiting Professor	SUNY Stony Brook
2008	Invited Lecturer	University of Dundee, Scotland

## Lectureships and Visiting Professorships

### By Academic Institution (excluding own affiliations)

University of Pennsylvania  
Tulane University  
Vanderbilt University  
National Institutes of Health & National Library of Medicine  
Emory University  
State University of New York, Buffalo  
Harvard Medical School  
Massachusetts General Hospital  
Beth Israel Hospital  
New York University  
Southwestern Medical School  
Imperial Cancer Research Fund Laboratories, London  
Tufts University  
Brown University  
Louisiana State University  
Pennsylvania State University  
Duke University  
Wilford Hall USAF Medical Center  
University of Tennessee  
McGill University  
Jefferson Medical College  
Medical College of Virginia  
University of Texas Medical Branch, Galveston  
University of Minnesota  
Northwestern University  
Bowman Gray School of Medicine, Wake Forest University  
University of Ottawa  
University of South Florida  
University of Florida  
Yale University  
St. John's Institute of Dermatology  
University of California at Davis  
Medical College of Georgia  
Sao Paulo University Hospital, Brazil  
North Carolina State University  
St. Thomas' Hospital (King's College-London & Univ. of London)  
St. Bartholomew's Hospital & Royal London School of Medicine and Dentistry, London  
University of Edinburgh  
Guy's Hospital, London  
University of Texas Health Sciences Center at Houston  
University of Cincinnati  
Women's College Hospital, University of Toronto  
University of Louisville  
Ohio State University  
Institute of Child Health & Great Ormond Hospital for Children, London  
Henry Ford Hospital  
Kansas University Medical Center  
Paracelsus Private Medical University, Salzburg, Austria  
SUNY Stony Brook  
University of Dundee

**By Organization (excludes research presentations \*)**

American Academy of Dermatology  
Dystrophic Epidermolysis Bullosa Research Association (DeBRA) of America  
South Central Dermatological Congress  
Annual Symposium on the Biology of the Skin, Gleneden Beach, OR  
Nashville Dermatological Society  
Southeastern Dermatological Society  
Florida Society of Dermatology  
American Dermatologic Society for Allergy and Immunology  
New England Dermatologic Society  
World Congress of Dermatology (West Berlin; New York City)  
American Society for Dermatopathology  
Canadian Dermatological Association  
Boston Dermatological Society  
Louisiana Dermatological Society  
Memphis Dermatologic Society  
Florida West Coast Society of Dermatology  
American Academy of Veterinary Dermatology  
American Dermatological Association  
New Mexico Dermatological Society  
DEBRA International (UK; Austria)  
Society for Pediatric Dermatology  
British Epidermo-Epidermiology Society  
DeBRA of Canada  
Central KY Dermatology Nurses Association  
Nashville Dermatology Society  
North Carolina Dermatology Association  
Kansas City Dermatological Society  
Montana Academy of Dermatology  
Nashville Dermatology Nurses Association

\* which have been given at meetings of the

Society for Investigative Dermatology (1982 - )  
Southern Society for Investigative Dermatology (1984 - )  
American Academy of Dermatology (1983 - )  
American Federation for Clinical Research (1982 - )  
American Society for Cell Biology (1986 - )  
several international symposia on inherited EB:  
London (1989; 2000; 2003); Philadelphia (1991; 1996);  
Chapel Hill (1994); Salzburg (1998)



**All Major Invited Lectures and Professorships (1982 - present):**

Guest lecturer, Univ. of Pennsylvania School of Medicine, Dept. of Dermatology, Philadelphia, PA, 12/82  
 Invited speaker, Pediatric Grand Rounds, UAB, Birmingham, AL, 8/83  
 Invited speaker, Pediatric Dermatology Symposium, American Academy of Dermatology, Chicago, IL, 12/83  
 Invited speaker, Medical Grand Rounds, UAB, Birmingham, AL, 1/84  
 Visiting professor, Tulane University, Dept. of Dermatology, New Orleans, 1/84  
 Invited speaker, Rheumatology Grand Rounds, UAB, Birmingham, AL, 11/84  
 Invited speaker, First National Conference, Dysmorphic Epidermolysis Bullosa Research Association of America, Washington, D.C., 11/84  
 Invited speaker, South Central Dermatological Congress XVII, New Orleans, 2/85  
 Invited speaker & visiting professor, Nashville Dermatological Society and Vanderbilt University, Division of Dermatology, 7/85  
 Invited speaker, 35th Annual Symposium on the Biology of the Skin, Gleneden Beach, OR, 10/85  
 Invited speaker, Monoclonal Antibody Symposium, American Academy of Dermatology, Las Vegas, NV, 12/85  
 Invited speaker, Southeastern Dermatological Society annual meeting, Nashville, TN, 4/86  
 Invited speaker, Florida Society of Dermatology annual meeting, Jacksonville, FL, 5/86  
 Invited speaker, Institute of Dental Research, UAB, Birmingham, AL, 5/86  
 Invited speaker, National Conference on Epidermolysis Bullosa, National Library of Medicine, Bethesda, MD, 9/86  
 Invited speaker, American Dermatologic Society for Allergy & Immunology annual meeting, Orlando, FL, 9/86  
 Visiting professor, Emory University, Dept. of Dermatology, Atlanta, GA, 10/86  
 Invited speaker, Dysmorphic Epidermolysis Bullosa Research Association of America annual meeting, New Orleans, LA, 12/86  
 Invited speaker, Advanced Immunology Course, American Academy of Dermatology, New Orleans, LA, 12/86  
 Invited speaker, Monoclonal Antibody Symposium, American Academy of Dermatology, New Orleans, LA, 12/86  
 Visiting professor, State University of New York at Buffalo, Depts. of Dermatology & Microbiology, Buffalo, NY, 2/87  
 Invited speaker, New England Dermatologic Society, Massachusetts General Hospital, Boston, MA, 3/87  
 Guest lecturer, Harvard Medical School - Beth Israel Hospital, Dept. of Dermatology, Boston, MA, 3/87  
 Invited speaker, Prenatal Diagnosis Symposium, World Congress of Dermatology, Berlin, 5/87  
 Invited speaker, Plastic Surgery Grand Rounds, UAB, Birmingham, AL, 9/87  
 Invited speaker, American Society for Dermatopathology annual meeting, San Antonio, TX, 12/87  
 Invited speaker, Dysmorphic Epidermolysis Bullosa Research Association of America annual meeting, San Antonio, TX, 12/87  
 Invited speaker, Monoclonal Antibody Symposium, American Academy of Dermatology, San Antonio, TX, 12/87  
 Invited speaker, Pediatric Grand Rounds, UAB, Birmingham, AL, 12/87  
 Howard Fox Lecturer, New York University School of Medicine, Dept. of Dermatology, New York, NY, 1/88  
 Invited speaker, Dept. of Medical Genetics, UAB, Birmingham, AL, 1/88  
 Invited speaker, Southwestern Medical School, Univ. of TX Health Sciences Center at Dallas, 1/88  
 Invited speaker, Southwestern Medical School, Univ. of TX Health Sciences Center at Dallas, 3/88  
 Invited speaker, Univ. of North Carolina School of Medicine, Dept. of Dermatology, Chapel Hill, NC, 4/88  
 Invited speaker, Canadian Dermatological Association annual meeting, Banff, Alberta, Canada, 6/88  
 Invited speaker, Neonatal/Obstetrics & Gynecology Grand Rounds, UAB, Birmingham, AL, 9/88  
 Invited speaker, Advanced Immunology, Immunodermatology, and Monoclonal Antibody Symposia, American Academy of Dermatology, Washington, DC, 12/88  
 Invited speaker, International Epidermolysis Bullosa Symposium, London, UK, 1/89  
 Invited speaker, Imperial Cancer Research Fund Laboratories, London, UK, 1/89  
 Invited speaker, St. John's Institute of Dermatology, London, UK, 1/89  
 Invited speaker, Tufts Univ. School of Medicine & New England Medical Center, Boston, MA, 3/89  
 Visiting professor, Brown University School of Medicine, Div. of Dermatology, Providence, RI, 5/89  
 Invited speaker, Univ. of North Carolina School of Medicine, Dept. of Dermatology, Chapel Hill, NC, 7/89  
 Invited speaker, International Update on Dermatology and Dermatopathology, Brighton, UK, 9/89  
 Visiting professor, Harvard Medical School - Massachusetts General Hospital & Beth Israel Hospital, Boston, MA, 10/89  
 Invited speaker, Boston Dermatological Society, Boston, MA, 10/89  
 Invited speaker, Louisiana State University School of Medicine, Department of Dermatology, New Orleans, LA, 11/89  
 Guest speaker, Louisiana Dermatological Society annual meeting, New Orleans, LA, 11/89  
 Invited speaker, American Society for Dermatopathology annual meeting, San Francisco, CA, 11/89  
 Visiting professor, Pennsylvania State University School of Medicine, Dept. of Dermatology, Hershey, PA, 4/90  
 Invited speaker, Westwood Conference on Clinical Dermatology, Hilton Head, SC, 10/90  
 Invited speaker, Duke University Medical Center, Department of Dermatology, Durham, NC, 11/90

Visiting consultant and distinguished guest lecturer, Department of Dermatology, Wilford Hall USAF Medical Center, Lackland AFB, San Antonio, TX, 1/91

Visiting professor, University of Tennessee School of Medicine, Dept. of Dermatology, Memphis, TN, 3/91

Guest speaker, Memphis Dermatologic Society, Memphis, TN, 3/91

Guest lecturer, McGill University, Faculty of Medicine, Department of Medicine, Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Canada, 7/91

Invited speaker, International Symposium on Epidermolysis Bullosa, Jefferson Medical College, Philadelphia, PA, 10/91

Invited speaker, Genetics and Genodermatoses course, American Academy of Dermatology annual meeting, Dallas, TX, 12/91

Invited participant, Workshop on Clinical Trials in Skin Diseases, National Institutes of Health / National Institute of Arthritis, Musculoskeletal, and Skin Diseases, Bethesda, MD, 1/92

Guest lecturer, Medical College of Virginia, Department of Dermatology, Richmond, VA, 3/92

Visiting professor, University of Texas Medical Branch, Department of Dermatology, Galveston, TX, 1992

Invited speaker, workshops on Epidermolysis Bullosa, Diseases of Skin Basement Membrane, and Prenatal Diagnosis, World Congress of Dermatology, New York City, 6/92

Invited faculty member, Research Methods in Clinical Research course (2 wk), Univ. of North Carolina at Chapel Hill, 7/92

Invited speaker, Genetics and Genodermatoses course, American Academy of Dermatology annual meeting, San Francisco, CA, 12/92

Julius Stone ADSAI Lecturer, Hawaii Dermatology Seminar, Hawaii, 2/93

Invited speaker, Scientific Workshop on the Epidemiology of Skin Diseases, National Institutes of Health / National Institute of Arthritis, Musculoskeletal, and Skin Diseases, Bethesda, MD, 3/93

Invited speaker, National Conference of the Dystrophic Epidermolysis Bullosa Research Association of America, Detroit, MI, 8/93

Invited speaker, Genetics and Genodermatoses course, American Academy of Dermatology annual meeting, Washington, DC, 12/93

Invited speaker, Departments of Pediatrics (Grand Rounds), University of Minnesota, Minneapolis, MN, 3/94

Invited speaker, Department of Dermatology, University of Minnesota, Minneapolis, MN, 3/94

Invited speaker, Duke University Medical Center, Division of Dermatology, Department of Medicine, Durham, NC, 3/94

Speaker and Program Director, International Symposium on Epidermolysis Bullosa, Chapel Hill, NC, 4/94

Visiting Professor, Department of Dermatology, Northwestern University Medical School and Children's Memorial Hospital, Chicago, IL, 4/94

Invited speaker, Bowman Gray School of Medicine, Wake Forest University, Department of Dermatology, Winston-Salem, NC, 1/95

Invited speaker, Genetics and Genodermatoses course, American Academy of Dermatology annual meeting, New Orleans, LA, 2/95

First Robert Jackson Lecturer, Division of Dermatology, University of Ottawa, Ottawa, Canada, 4/95

Invited participant, National Skin Diseases Data Workgroup meeting, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 9/95 & 2/96

Invited speaker, Southeastern Consortium for Dermatology, Chapel Hill, NC, 10/95

Invited speaker, National Conference of the Dystrophic Epidermolysis Bullosa Research Association of America, Houston, TX, 11/95

Invited speaker, Preparation for Recertification Course, American Academy of Dermatology annual meeting, Washington, DC, 2/96

Guest professor, University of South Florida College of Medicine, Department of Dermatology, Tampa, FL, 3/96

Invited speaker, Florida West Coast Society of Dermatology, Tampa, FL, 3/96

Invited speaker, Symposium on EB, Jefferson Medical College, Philadelphia, PA, 4/96

Invited speaker, Preparation for Recertification Course, American Academy of Dermatology annual meeting, San Francisco, CA, 3/97

Invited speaker, American Academy of Veterinary Dermatology annual meeting, Nashville, TN, 4/97

Guest speaker, New Mexico Dermatological Society, Albuquerque, NM, 4/97

Speaker and scientific program chairman, Dystrophic Epidermolysis Bullosa Research Association of America National Conference '97, Chapel Hill, NC, 8/97

Guest speaker, Department of Dermatology, Vanderbilt University School of Medicine, Nashville, TN, 1/98

Invited speaker, DEBRA International Meeting 1998, Salzburg, Austria, 5/98

Invited speaker, Satellite Symposium on Hereditary and Acquired Bullous Dermatoses of the International Investigative Dermatology 1998 Meeting, Salzburg, Austria, 5/98

Visiting lecturer, University of Florida College of Medicine, Division of Dermatology, Gainesville, FL, 6/98

Invited speaker, Department of Dermatology, Yale University School of Medicine, New Haven, CT, 11/98

Visiting professor, St. Thomas' Hospital and St. John's Institute of Dermatology, London, UK, 12/98

Invited speaker, Rheumatology Grand Rounds, University of North Carolina, 1/99

Invited speaker, Department of Dermatology, University of Texas Medical Branch at Galveston, 4/99

Co-Chair, Second International EB Consensus Meeting on Diagnosis and Classification, Chicago, IL, 5/99

Invited participant, Consensus Meeting on Cicatricial Pemphigoid, Northwestern Univ., Chicago, IL, 5/99

Invited speaker, Department of Dermatology, University of California at Davis, Sacramento, CA, 5/99  
 Invited participant, National Skin Diseases Data Workgroup meeting, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rockville, MD, 6/99  
 Invited participant, NHANES Dermatology Workshop, Center for Disease Control and Prevention, National Center for Health Statistics, Rockville, MD, 6/99  
 Guest speaker, Society of Pediatric Dermatology annual meeting, Traverse City, MI, 7/99  
 Invited speaker and scientific program co-chairman, national meeting of the Dystrophic Epidermolysis Bullosa Research Association of America, Torrance, CA, 8/99  
 Invited participant, symposium on "Epidemiology and Health Services Research - Prospects for Development in Skin Diseases," co-sponsored by the Carl J. Herzog Foundation and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 9/99  
 Invited participant and organizing committee member, International EB Research Visioning and Consensus Meeting, co-sponsored by DebRA-Europe and DebRA of America, Newark, NJ, 10/99  
 Invited speaker, Division of Dermatology, Duke University Medical Center, Durham, NC, 12/99  
 Guest speaker, Division of Dermatology, Medical College of Georgia, and Augusta Dermatological Society, Augusta, GA, 2/00  
 Guest speaker, Department of Dermatology, Sao Paulo University Hospital, and "II Jornada Dermatológica do HC-FMUSP," Sao Paulo, Brazil, 4/00  
 Invited speaker, Dermatology Symposium, North Carolina State University College of Veterinary Medicine, Raleigh, NC, 6/00  
 Invited speaker, EB 2000 International Symposium, London, England, 9/00  
 Guest speaker, Centre for Cutaneous Research, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, England, 11/00  
 Guest lecturer, St. John's Institute of Dermatology, London, England, 12/00  
 Visiting Professor & Visiting Consultant in Dermatology, Department of Cellular and Molecular Pathology, St. John's Institute of Dermatology; Guy's, King's, and St. Thomas' Medical School; and King's College - London, London, England, 9/00 - 3/01  
 Guest speaker, Department of Dermatology, University of Edinburgh, Scotland, 2/01  
 Invited speaker, British Epidermo-Epidemiology Society annual meeting, London, 3/01  
 Invited speaker, Department of Public Health Services, Guy's Hospital, London, England, 3/01  
 Invited speaker and organizing committee member, national meeting of DebRA-US, Philadelphia, PA, 11/01  
 Guest lecturer, Department of Dermatology, University of Texas Health Sciences Center at Houston, Houston, TX, 1/02  
 Proctor and Gamble Lecturer, Department of Dermatology, Univ. of Cincinnati, 2/02  
 Visiting Professor, Department of Dermatology, Brown University, Providence, RI, 4/02  
 Guest lecturer, Division of Dermatology, Duke University Medical Center, Durham, NC, 5/02  
 Keynote speaker, DebRA-Canada annual meeting, Women's College Hospital, Toronto, Canada, 6/02  
 10<sup>th</sup> Bernice Fine Lecturer in Cutaneous Medicine, University of Louisville School of Medicine, Louisville, KY, 12/02  
 Invited speaker, Robin Eady Festschrift, King's College London & St. John's Institute of Dermatology, London, UK, 4/03  
 Invited speaker, Division of Dermatology, University of Louisville School of Medicine, Louisville, KY, 4/03  
 Invited speaker, Department of Medicine, Ohio State University, 7/03  
 Invited speaker, Division of Dermatology, University of Louisville School of Medicine, Louisville, KY, 9/03  
 Invited speaker and Co-Chair, "Clinical Management of Children and Adults with Epidermolysis Bullosa: A Multidisciplinary International Symposium", Institute of Child Health and the Great Ormond Street Hospital for Children NHS Trust, London, UK, 10/03  
 Invited speaker, North Carolina Dermatology Association winter meeting, Pinehurst, NC, 1/04  
 Invited speaker, annual meeting of the Association for Proficiency in Skin Immunopathology, held in conjunction with the American Academy of Dermatology, Washington, DC, 2/04  
 Guest speaker, Nashville Dermatology Society and Vanderbilt University Division of Dermatology, 5/04  
 Invited speaker, Division of Dermatology, University of Louisville School of Medicine, Louisville, KY, 5/04  
 Guest speaker, Grand Rounds, Department of Dermatology, Henry Ford Hospital, Detroit, MI, 6/04  
 Invited speaker, Division of Dermatology, University of Louisville School of Medicine, Louisville, KY, 8/04  
 Invited speaker, Kansas City Dermatological Society, Kansas City, KS, 11/04  
 Invited speaker, Dept of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, 1/05  
 Invited speaker, Division of Dermatology, University of Louisville School of Medicine, Louisville, KY, 8/05  
 Invited overseas speaker, Keratin and Genodermatoses Symposium, Royal Society (London), London, UK, 9/05  
 Invited speaker, Medical Grand Rounds, Vanderbilt University School of Medicine, Nashville, TN, 10/05  
 Invited speaker, Division of Pediatric Gastroenterology, Vanderbilt University School of Medicine, Nashville, TN, 10/05  
 Invited speaker, Montana Academy of Dermatology, Big Sky, MT, 1/06  
 Invited speaker, Nashville Dermatology Nurses Association, Nashville, TN, 4/06  
 Visiting Professor, Department of Dermatology, Paracelsus Private Medical University, Salzburg, Austria, May 15-25, 2006  
 Invited speaker and conference co-organizer, DebRA of America National Patient Care Conference, Nashville, TN, 6/06  
 Visiting Professor, Department of Dermatology, SUNY Stony Brook, 10/06

Invited Speaker, 1st International Symposium on Thymosins in Health and Disease, George Washington University, Washington, DC, 3/07  
Chair, Third International EB Consensus Meeting on Diagnosis and Classification, Vienna, Austria, 5/07  
Invited lecturer, Division of Dermatology, University of Louisville School of Medicine, 2/08  
Invited speaker, EB and Cancer Symposium, University of Dundee, Dundee, Scotland, 3/08

## Professional Societies:

### Medical:

Alpha Omega Alpha Honor Medical Society	1975
American College of Physicians (Fellow)	1984
American Academy of Dermatology (Fellow)	1981
American Dermatological Association	1996
American Federation for Clinical Research	
American Dermatologic Society for Allergy and Immunology	
Board of Directors	1986 - 1987
Royal Society of Medicine (London) (Overseas Fellow)	1993
Member, Section on Dermatology	2001
Medical Dermatology Society	
Dermatology Foundation	
International Society of Dermatology (inactive)	
Southeastern Dermatological Association (inactive)	
Lexington Medical Society (inactive)	
Kentucky Medical Association (inactive)	
Kentucky Dermatological Society (inactive)	
Central Kentucky Dermatologic Association (inactive)	
Tennessee Dermatology Society	2004
Nashville Dermatology Society	2004
American Contact Dermatitis Society	2006
Royal College of Physicians (London) (Fellow)	2007

### Medical Research:

Society for Investigative Dermatology (SID):	1983 - present
Secretary-Treasurer, Southern SID	1985 - 1986
Vice-President, Southern SID	1986 - 1987
President, Southern SID	1987 - 1988
Southern Society for Clinical Investigation	1988
Dystrophic Epidermolysis Bullosa Research Association (DebRA) of America	
Scientific Advisory Board	1985 - present
Board of Trustees	1989 - 2007
DebRA of the United Kingdom and Europe	
International Review Board (research proposals)	1998 - present
Japanese Society for Investigative Dermatology, Overseas Member	1994 - 2002
Association for Patient-Oriented Research	2002-2005

### Epidemiological:

International Dermatoepidemiology Association	
Chair, Membership and Nominations Committee	1996 - 1997
American Public Health Association	
American College of Epidemiology	

### Other Scientific:

American Society for Cell Biology (FASEB) (inactive)	
American Association of Immunologists (inactive)	
Society for Mucosal Immunology (inactive)	
Alabama Dermatological Society (inactive)	
North Carolina Dermatology Society (inactive)	
National Association of Veterans Administration Dermatologists (inactive)	

## Other Professional Activities:

### A. National organizations

#### American Academy of Dermatology:

Member, Task Force on Immunopathology	1984 - 1986
Member, Task Force on Genetics	1989 - 1992
Member, Committee on NIAMS Liason	1990 - 1992
Member & Judge, Scientific Program Committee, Residents and	

Dystrophic Epidermolysis Bullosa Research Association of America, Inc.  
(D.E.B.R.A. of America, New York, NY):

Scientific Advisory Board	1985 - present
Research Goals Committee	1988 - 1989
Grants and Scientific Review Committee	1989 - 1990, and 1996 - 2007
Board of Trustees	1989 - 2007
Long Term Strategic Planning Committee	1992 - 1995
Scientific Program Chairman, '97 National Meeting	1997
Scientific Program Co-Chairman, '99 National Meeting	1999
Organizing Committee member, Visioning / Consensus Meeting	1999
Program Committee member, '06 National Meeting	2005 - 2006

National Epidermolysis Bullosa Registry (NEBR), NIH / NIAMS:

Steering Committee	1986 - present
Chairman	1992 - present
Subcommittee on Diagnostic Criteria and Classification	
Chairman	1988 - present
Principal Investigator, NEBR Southeastern Clinical Center	1986 - 1997
Principal Investigator, NEBR Data Coordinating Center, and Overall Project Head	1992 - present

National Institutes of Health (NIH):

NIAMS National Skin Diseases Data Workgroup, member	1995 - present
NHANES Dermatology Workgroup, member	3/98 - present
NIH Advisory Committee (Freedom of Information Act/A-110) regarding the OMB A110 regulation on public accessibility to federally funded data	1999

Epidermolysis Bullosa Medical Research Foundation (EBMRF, Provo, UT):

Scientific Advisory Board	1997 - present
---------------------------	----------------

National Alopecia Areata Registry, NIH / NIAMS:

Advisory Committee	2000 - present
--------------------	----------------

**B. International organizations**

Dystrophic Epidermolysis Bullosa Research Association of the United Kingdom  
and Europe (D.E.B.R.A.-U.K./International, based in London, England):

International Grant Review Board for the Medical and Scientific Advisory Panel (1st American member so appointed)	
MSAP member	1998 - present
Member, Clinical Grants Review Subpanel	2005 - present
Vice-Chair	2005 - 2008
Chair	2008 - present
EB Skin Cancer Task Force member	2006 - present

International Dermatoepidemiology Society:

**C. Study section / peer review activities****1. National****a. National Institutes of Health**

Member, Ad Hoc Special Study Section, NIH General Medicine A-2	9/86
---	------

Reviewer and participant, NIAMS site visit, program project grant, Jefferson Medical College, Philadelphia	3/87
---	------

Chairman, NIAMS site visit, program project grant, Dept. of Dermatology, University of Pennsylvania	6/88
--	------

Reviewer and participant, NIAMS supplemental application to funded program project grant (Jefferson Medical College)	12/90
---	-------

Member and reviewer, Ad Hoc Special Study Section, NIAMS	3/91
--	------

Reviewer and participant, NIAMS site visit, program project grant, Jefferson Medical College, Philadelphia	4/92
---	------

Reviewer, NIAMS Ad Hoc Special Study Section (Rare Disease Registry Contracts, RFA-003), Bethesda, MD	5/94
--	------

Ad hoc reviewer, NCI Epidemiology and Disease Control Study Section, Subcommittee 2	10/96
--	-------

Ad hoc reviewer, NIDR Oral Biology and Medicine-I (OBM-I) Study Section	10/98
---	-------

Member, NIAMS Ad Hoc Special Study Section (Multipurpose Clinical Research Centers)	7/99
--	------

Member, NIAMS Ad Hoc Special Study Section (K23 & K24 Career Development Awards)	10/99
---	-------

Ad hoc reviewer, NCI Epidemiology and Disease Control Study Section, Subcommittee 2 (EDC-2)	12/99
--	-------

**b. Veterans Administration**

Outside Reviewer, Merit Review Proposals	Spring 1985 Fall 1986 Spring 1989 Fall 1994
--	--

**c. Private Foundations (United States)**

Grant reviewer, March of Dimes Birth Defects Foundation	10/87
--	-------

Grant reviewer, National Psoriasis Foundation	12/93
---	-------

Grant reviewer, Dystrophic Epidermolysis Bullosa Research Association (D.E.B.R.A.) of America	1989 - present
--	----------------

**2. International**

Grant reviewer, Swiss National Science Foundation	5/91
Grant reviewer, The Wellcome Trust, London, UK	9/95; 4/98; 3/99; 4/03
Grant reviewer, Special Trustees for St. Thomas' Hospital, London, UK	2/98
Committee member, International Review Board (for grant proposals), D.E.B.R.A.-U.K./Europe, London, England	6/98 – present (twice yearly)
British Skin Foundation -- grants referee	2001
German Federal Ministry for Education and Research, Bonn, Germany	5/02, 5/08
<b>3. <u>Local (Institutional)</u></b>	
Reviewer (grants), UAB Comprehensive Cancer Center	9/86
<b>4. <u>Other</u></b>	
Reviewer, Resident/Fellow Award, Archives of Dermatology	1993 - 96
Reviewer (for abstract selection at annual regional meeting), Southern Society for Investigative Dermatology	1985 - 88
Reviewer (for abstract selection at annual national meeting), Society for Investigative Dermatology	1993, 1995
Reviewer (for abstract selection at annual national meeting), International Dermatoepidemiology Association	1996

#### **D. Editorial activities**

##### **1. Journals**

Deputy Editor, <u>Journal of Investigative Dermatology</u>	1992 - 93
Editorial Board member, <u>Clinical and Experimental Dermatology</u>	1994 - 98
Editorial Board member, <u>Journal of the American Academy of Dermatology</u>	2003 - 08

##### **2. Books**

Section Editor (Cutaneous Biology/Oncogenesis), <i>Cutaneous Surgery</i> , 1986	
Editor, <i>Bullous Diseases</i> (Igaku-Shoin Medical Publishers), 1993	
Editor-in-Chief, <i>Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry</i> . Johns Hopkins University Press, May 1999	
Co-Editor and Author, <i>Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy</i> . Springer Verlag GmbH, Wien New York, 2008 (in press).	



3. Other

Contributor, Dermatology Lexicon Project

2004 - present

**E. Reviewer (medical and scientific journals)**

Archives of Internal Medicine	1982 - present
Journal of Investigative Dermatology	1983 - present
Archives of Dermatology	1984 - present
Journal of American Academy of Dermatology	1984 - present
Journal of Oral Pathology	1984 - present
Archives of Pathology & Laboratory Medicine	1984 - present
Arthritis and Rheumatism	1985 - present
American Journal of Medical Sciences	1985 - present
Collagen and Related Research	1985 - present
Laboratory Investigation	1986 - present
American Journal of Medicine	1986 - present
Pediatric Dermatology	1986 - present
American Journal of Kidney Diseases	1987 - present
Journal of Immunology	1987 - present
American Journal of Dermatopathology	1988 - present
Journal of Clinical Investigation	1989 - present
New England Journal of Medicine	1990 - present
British Journal of Dermatology	1991 - present
American Journal of Hematology	1991 - present
Journal of Cutaneous Pathology	1991 - present
Clinical and Experimental Dermatology	1993 - present
Journal of Dermatological Science	1993 - present
Archives of Dermatological Research	1993 - present
Lancet	1995 - present
Journal of Histochemistry and Cytochemistry	1997 - present
Journal of Cutaneous Medicine and Surgery	1998 - present
American Journal of Human Genetics	1999 - present
Acta Dermato-Venereologica	2002 - present
Journal of the European Academy of Dermatology & Venereology	2003 - present
Human Genetics	2004 - present
Pediatric Drugs	2007 - present
Indian Journal of Cancer	2008 - present

**F. University Teaching Responsibilities, 1983 - present**

(excluding those directly related to the Dermatology Residency Program):

**University of Alabama at Birmingham (1983 - 1990):**

i. Department of Dermatology-based:

Second Year Medical School Curriculum, Dermatology Course  
Faculty member & lecturer

1983 - 1990

**University of North Carolina at Chapel Hill (1990 - 2002):**

i. Department of Dermatology-based:

Second Year Medical School Curriculum, Dermatology Course  
Faculty member / lecturer

Spring 1991 - 2002

2. Other Formal University Teaching Activities:a. School of Medicine

Faculty member, "Research Methods in Clinical Research for research fellows and chief residents," course co-sponsored by the Depts. of Medicine & Surgery

Summers 1992, 1994,  
2001

Faculty member and seminar leader, Clinical Epidemiology and Preventive Medicine course (required of all 2nd year medical students), administered through the Dept. of Social Medicine, (~ 36 contact hrs/year)

1993 - 1998

b. School of Public Health

Faculty member, Epidemiology 160 (Principles of Epidemiology) course, UNC School of Public Health

1994 - 1996

Lecturer, Epidemiology 276 (Occupational Epidemiology) course, UNC School of Public Health

1995, 1996

University of Louisville School of Medicine (2002 - present)

Lecturer, Division of Dermatology

12/02, 4/03, 9/03, 4/04, 8/04, 8/05, 2/08

**G. Miscellaneous Professional Activities**1. Administrativea. Diagnostic Laboratory Activities

Director and Founder, Laboratory of Immunodermatology, University of Alabama Health Services Foundation (regional diagnostic immunofluorescence laboratory)

1984 - 90

Co-Director and Founder, Laboratory of Immunodermatology, University of North Carolina at Chapel Hill (regional diagnostic immunofluorescence laboratory)

1990 - 2000

Director and Founder, Laboratory of Immunodermatology, Vanderbilt University School of Medicine (regional diagnostic immunofluorescence laboratory)

2006 - present

Head and Founder, Contact Dermatitis and Patch Testing Clinic Vanderbilt University School of Medicine

2006 - present

b. Training Program Director

Program Director, 1st nationally approved residency training program in dermatologic immunology/diagnostic and laboratory

immunology (via the American Board of Dermatology), Dept. of Dermatology, University of Alabama at Birmingham	1986 - 90
Program Director, Clinical Dermatocpidemiology Fellowship, Univ. of North Carolina at Chapel Hill	1998 - 2002
Program Director, D.E.B.R.A. Clinical Investigation Fellowship (for clinical research in inherited epidermolysis bullosa), Univ. of North Carolina at Chapel Hill	1999 - 2002
Residency Program Director, Department of Dermatology, Univ. of North Carolina at Chapel Hill	7/00 - 1/02
c. <u>Research Project Director (Multicenter only)</u>	
National Epidermolysis Bullosa Registry:	
Southeastern Clinical Center (Principal Investigator)	1986 - 1997
Data Coordinating Center (Principal Investigator)	1992 - 2002
Overall Project Head	1992 - 2002
d. <u>Organizer and/or Chair, National and International Conferences</u>	
Program Chairman, Consensus Conference on Classification and Diagnostic Criteria for Inherited Epidermolysis Bullosa, Washington, DC	December 1988
Program Director & Chairman of the Organizing Committee, International Symposium on Epidermolysis Bullosa, co-sponsored by the National Institutes of Health and the Univ. of North Carolina at Chapel Hill, Chapel Hill, NC	April 1994
Scientific Program Chairman, 1997 National Meeting of the Dystrophic Epidermolysis Bullosa Research Association (D.E.B.R.A.) of America, Chapel Hill, NC	August 1997
Program Co-Chairman, Second International Consensus Conference on Revised Classification and Diagnostic Criteria for Inherited Epidermolysis Bullosa, Chicago, IL	May 1999
Scientific Program Co-Chairman, 1999 National Meeting of D.E.B.R.A. of America, Torrence, CA	August 1999
Member, Organizing Committee, International Visioning and Consensus Meeting of D.E.B.R.A. of America and D.E.B.R.A.-Europe, Newark, NJ	October 1999
Member, Steering Committee, Epidermolysis Bullosa 2000 Symposium, London, U.K. (held in September 2000)	1998 - 2000
Scientific Program Organizing Committee member, 2001 National Meeting of D.E.B.R.A. of America, Philadelphia, PA	December 2001
Co-Chairman, Scientific Workshop on Epidermolysis Bullosa, 20th World Congress of Dermatology, Paris, France	July 2002
Scientific Program Co-Chairman, 2006 National Meeting of D.E.B.R.A. of America, Nashville, TN	June 2006
Member, Organizing Committee, International Visioning and Consensus Meeting of D.E.B.R.A.-International ("EB 2006"), Dublin, Ireland	October 2006

Program Chair & Planning Committee, Third International Consensus  
Conference on Revised Classification and Diagnostic Criteria  
for Inherited Epidermolysis Bullosa, Vienna, Austria

May 2007

c. Task force (national) and other academic committee activities

Task Force member, Archives of Dermatology Annual Trainee  
Award

1993 - 96

Ph.D. dissertation committee member (Experimental Pharmacology),  
College of Veterinary Medicine, North Carolina State Univ.

1994 - 96

f. Consultant: Blue Cross & Blue Shield of North Carolina

2000 - 2002

g. Other professional administrative activities

Head, Dermatology Clinical Trials Workgroup, UNC-CH

8/01 – 8/02

Selector of speakers for the annual Bernice Fine Lectureship  
in Cutaneous Medicine, Division of Dermatology,  
Univ. of Louisville School of Medicine (endowed by  
Dr. Fine's father, a dermatologist and Class of 1935  
at the Univ. of Louisville School of Medicine)

1991 - present

Director, Bullous Diseases Clinic, Vanderbilt

2004 - present

Director, Contact Dermatitis Clinic, Vanderbilt

2006 - present

Thymosin beta-4 clinical trial Core Review Committee member

2007 - present

2. Development of educational teaching tools

Creator and author, Dr. Cutis, a prototypic interactive multimedia  
computer program for the teaching of basic dermatologic principles  
using the case study approach

Spring 1996

Co-author and editor, electronic syllabus for the second year  
medical school curriculum at UNC-CH

Spring 1998

Creator and co-author (with Dr. Ho-Jin Kim) of an interactive multimedia  
computer program for the teaching of pediatric dermatology  
using the case study approach

1998

Co-author (with Prof. Robin Eady) of an interactive CD-ROM on  
inherited epidermolysis bullosa

2000

Co-author of "Questions and Answers about Epidermolysis Bullosa,"  
an educational pamphlet produced and distributed by the  
National Institutes of Health (NIAMS) for use by patients and  
families of EB patients, lay organizations, and non-dermatologists,  
NIH Publication No. 03-7038  
[[www.niams.nih.gov/hi/topics/epidermolysis\\_bullosa/epidermolysis\\_bullosa.htm](http://www.niams.nih.gov/hi/topics/epidermolysis_bullosa/epidermolysis_bullosa.htm)]

June 2003

3. Development of UNC Department of Dermatology manuals, syllabus, other

Editor & Co-Author, Second year medical school syllabus on dermatology, UNC-CH	Spring 1995
Creator of revised didactic curriculum for UNC Dermatology residency program	Spring 2001
Author of <i>Dermatology Residency Handbook</i> (for UNC Program)	Spring 2001
Co-author, UNC Dept. of Dermatology web site	Spring 2001
  
4. National EB Registry-related educational materials

Author of web site for Internet-accessible NEBR outcome data	2000, 2002
--	------------
  
5. International EB Registry (via Engelhorn Foundation, Luxembourg)

Author of web site for Internet-accessible patient enrollment and data collection	2001
---	------
  
6. Other teaching activities

<u>Galderma Pre-Board Review Course</u>	2003 - present
Faculty member and lecturer ("Vasculitis, Connective Tissue Diseases, and Bullous Diseases") for a nationally-based yearly course for preparation for the American Board of Dermatology certification examination (attended by approx. 80% of all senior dermatology residents)	
 <u>Dermatology Associates of KY</u>	
Lecturer, annual CME course for primary care physicians	2003
  
7. Other board memberships and consultantships

RegeneRx Biopharmaceuticals, Inc. Member, Scientific and Medical Advisory Board	2004 - present
Contributor / Co-Editor on "Epidermolysis Bullosa" to the Dermatology Lexicon project	2004

#### H. Medical Licensure:

Massachusetts (# 43461; currently inactive)	1978 - 1995
Maryland (# D26864; currently inactive)	1981 - 1983
Alabama (# 10869)	1983 - present
North Carolina (# 38938)	1990 - present
Kentucky (# 37227)	2002 - present
Ohio (#35-08-3856-F)	2004 - 2007
Virginia (# 0101236352)	2004 - 2008
Tennessee (#38923)	2004 - present

#### I. Research Trainees, Students, and Postdoctoral Fellows:

<u>Name</u>	<u>Sponsoring or Previous Institution</u>	<u>Dates (duration)</u>
Elizabeth Spiers, M.D. (med. student)	Univ. of Texas, Galveston	1986 (3 months)
Joy Jester, M.D. (dermatol. resident)	Univ. of Colorado	1986 (6 months)
James Krell, M.D. (med. student)	Harvard Medical School	1988 (3 months)
Yuji Horiguchi, M.D., Ph.D. (postdoc.)	Kyoto University	1987 - 1989
Li Zeng, M.D. (postdoc. fellow)	China Medical University	1992 - 1995
Kathryn Riddelle, Ph.D. (postdoc.)	Northwestern University	1993 - 1995
Amy Stein, M.D. (clinical research fellow)	SUNY-Downstate / UNC-CH	2000 - 2001
Sarah Cash, M.D. (clin. research fellow)	West Virginia University	2001 - 2002
Joy De Leoz, M.D. (clin. research fellow)	Bicol Christian School of Medicine, Philippines	2001 - 2002
David Todd Devries, M.D. (medical student; Doris Duke Foundation Predoctoral Fellowship Program)	Univ. of North Carolina	2001 - 2002
Matthew Hall, M.D. (medical student)	Vanderbilt University	July 2005

## College alumni-related

Chapel Hill, NC:	
Committee member	1976-78, and 1993 - 1999
Director	1994 - 1999

Birmingham, AL:	
Committee member	1988 - 1990

Yale Club of Alabama, Vice-President	1989 - 1990
--------------------------------------	-------------

## Medical school alumni-related

University of Kentucky Medical Alumni Association  
Board Member (Representative, Class of 1976)  
Committee member, Alumni Association Awards Committee

### Miscellaneous citations

	listed in <i>American Men and Women of Science</i>	1986; 1995-96; 2002
" "	<i>Best Doctors in America, 1992-93</i>	
" " " "	" " " ", 1994-95	
" " " "	" " " ", 1998	
" " " "	" " " ", 2001-02	
" " " "	" " " ", 2005-06	
" " " " " "	" " " " " ", 2007-08	
" "	<i>Best Doctors in America: Southeast Region, 1996-97</i>	
" "	<i>International Who's Who in Medicine</i> , 2nd ed.	1994
" "	<i>Who's Who in the South and Southwest</i> , 25th ed.	1996
" "	<i>Who's Who in Medicine and Healthcare</i> , 1st ed.	1997-98
" "	<i>Who's Who in Medicine and Healthcare</i> , 2nd ed.	1999-2000
" "	<i>Who's Who in the World</i> , 15th ed.	1998
" " "	<i>Best Doctors in North Carolina (in Business North Carolina,</i> <i>July 2002 issue)</i>	2002
" "	<i>2000 Eminent Scientists of Today</i> , 1 <sup>st</sup> ed.	2003
" "	<i>Who's Who in America - 2006</i>	2004
" "	<i>Who's Who in America - 2008</i>	2008

Vitae, Jo-David Fine, revised 7/17/08

## Publications

### A. Original Investigative Studies (Laboratory and Clinical)

1. Fine JD and Rees ED: Bence Jones protein: detection and implications. N Engl J Med 290: 106-107, 1974.
2. Fine JD, Luke RG, and Rees ED: Renal cytotoxic effects of Bence Jones protein. Lancet 1: 50, 1977.
3. Smith SB, Harriett TJ, Murphy GF, Halperin AJ, Newell JB, Fallon JT, Fine JD, and Mihm MC Jr: Linear IgA bullous dermatosis v dermatitis herpetiformis: quantitative measurements of dermoepidermal alterations. Arch Dermatol 120: 324-328, 1984.
4. Fine JD, Breathnach SM, Hintner H, and Katz SI: KF-1 monoclonal antibody defines a specific basement membrane antigenic defect in dystrophic forms of epidermolysis bullosa. J Invest Dermatol 82: 35-38, 1984.
5. Fine JD, Neises GR, and Katz SI: Immunofluorescence and immunoelectron microscopic studies in cicatricial pemphigoid. J Invest Dermatol 82: 39-43, 1984.
6. Fine JD, Smith LT, Holbrook KA, and Katz SI: The appearance of four basement membrane zone antigens in developing human fetal skin. J Invest Dermatol 83: 66-69, 1984.
7. Fine JD, Breathnach SM, Fox PA, Neises GR, Stanley JR, and Katz SI: Monoclonal antibodies in dermatologic research: studies with a unique keratinocyte-specific cell-surface antigen defined by a monoclonal antibody (KF-2). Am J Dermatopathol 7: 171-179, 1985.
8. Fine JD: Epidermolysis Bullosa: Variability of expression of cicatricial pemphigoid, bullous pemphigoid, and epidermolysis bullosa acquisita antigens. J Invest Dermatol 85: 47-49, 1985.
9. Fine JD: Cicatricial pemphigoid, bullous pemphigoid, and epidermolysis bullosa acquisita antigens: differences in organ and species specificities and localization in chemically-separated human skin of three basement membrane antigens. Collagen Rel Res 5: 369-377, 1985.
10. Fine JD and Griffith RD: A specific defect in glycosylation of epidermal cell membranes. Definition in skin from patients with epidermolysis bullosa simplex. Arch Dermatol 121: 1292-1296, 1985.
11. Fine JD and Gay S: LDA-1: A ubiquitous non-collagenous lamina densa component of basement membrane detected by monoclonal antibody technique. J Invest Dermatol 86: 286-289, 1986.
12. Fine JD and Gay S: LDA-1 monoclonal antibody: an excellent reagent for immunofluorescence mapping studies in patients with epidermolysis bullosa. Arch Dermatol 122: 48-51, 1986.
13. Fine JD, Redmar DA, and Goodman AL: Sequence of reconstitution of seven basement membrane components following split-thickness wound induction in primate skin. Arch Dermatol 123: 1174-1178, 1987.
14. Epstein A, Hendricks J, Sanchez R, Solomon A, and Fine JD: Persistent subepidermal blistering in split-thickness skin graft sites: ultrastructural and antigenic features simulating dystrophic or immunofluorescence-negative acquired epidermolysis bullosa. Arch Dermatol 124: 244-249, 1988.
15. Fine JD, Appell ML, Green LK, and Sams WM Jr: Pemphigus vulgaris: combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis and azathioprine. Arch Dermatol 124: 236-239, 1988.
16. Fine JD and Couchman JR: Chondroitin-6-sulfate-containing proteoglycan: a new component of human skin dermoepidermal junction. J Invest Dermatol 90: 283-288, 1988.
17. Fine JD and Johnson L: Efficacy of systemic phenytoin in the treatment of junctional epidermolysis bullosa. Arch Dermatol 124: 1402-1406, 1988.
18. Gay S, Fine JD, and Storer JS: Autoantibodies to extracellular collagen matrix components in epidermolysis bullosa and other bullous diseases. Arch Dermatol Res 280: 333-337, 1988.



19. Gammon WR, Heise ER, Burke WA, Fine JD, Woodley DT, and Briggaman RA: Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol 91: 228-232, 1988.
20. Fine JD, Eady RAJ, Levy ML, Hejtmancik JF, Courtney KB, Carpenter RJ, Holbrook KA, and Hawkins HK: Prenatal diagnosis of dominant and recessive dystrophic epidermolysis bullosa: application and limitations in the use of KP-1 and LH 7:2 monoclonal antibodies and immunofluorescence mapping. J Invest Dermatol 91: 465-471, 1988.
21. Fine JD, Tying S, and Gammon WR: The presence of intra-lamina lucida blister formation in epidermolysis bullosa acquisita: possible role of leukocytes. J Invest Dermatol 92: 27-32, 1989.
22. Fine JD and Johnson L: Evaluation of the efficacy of topical parfenac in epidermolysis bullosa simplex: a double blind placebo-controlled crossover trial. Arch Dermatol 124: 1669-1672, 1988.
23. Fine JD and Couchman JR: Chondroitin 6-sulfate proteoglycan but not heparan sulfate proteoglycan is abnormally expressed in skin basement membrane from patients with dominant and recessive dystrophic epidermolysis bullosa. J Invest Dermatol 92: 611-616, 1989.
24. Horiguchi Y, Couchman JR, Ljubimov AV, Vasiliev JM, Yamasaki H, and Fine JD: Organ specificity, ontogeny, and ultrastructural localization of the core protein of heparan sulfate proteoglycan, a new component of human skin basement membrane zone. J Histochem Cytochem 37: 961-970, 1989.
25. Fine JD, Horiguchi Y, Jester J, and Couchman J: Detection and partial characterization of a mid-lamina lucida - hemidesmosome - associated antigen (19-DEJ-1) present within human skin. J Invest Dermatol 92: 825-830, 1989.
26. Fine JD, Horiguchi Y, and Couchman JR: 19-DEJ-1, a hemidesmosome-anchoring filament complex-associated monoclonal antibody. Definition of a new skin basement membrane antigenic defect in junctional and dystrophic epidermolysis bullosa. Arch Dermatol 125: 520-523, 1989.
27. Rusenko KW, Gammon WR, Fine JD, and Briggaman RA: The carboxyl-terminal domain of type VII collagen is present at the basement membrane in recessive dystrophic epidermolysis bullosa. J Invest Dermatol 92: 623-627, 1989.
28. Tying SK, Chopra V, Johnson L, Fine JD: Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa. Arch Dermatol 125: 797-800, 1989.
29. Fine JD, Tamura T, and Johnson L: Blood vitamin and trace metal levels in epidermolysis bullosa. Arch Dermatol 125: 374-379, 1989.
30. Wright JT, Fine JD, and Johnson LB: Oral soft tissues in hereditary epidermolysis bullosa. Oral Surgery, Oral Medicine, Oral Pathology 71: 440-446, 1991.
31. Fine JD, Holbrook KA, Elias S, Anton-Lamprecht I, and Rauskolb R: Applicability of 19-DEJ-1 monoclonal antibody for the prenatal diagnosis or exclusion of junctional epidermolysis bullosa. Prenatal Diagnosis 10: 219-229, 1990.
32. Horiguchi Y, Fine JD, Ljubimov AV, Yamasaki H, and Couchman JR: Entactin: ultrastructural localization of a ubiquitous basement membrane glycoprotein in mouse skin. Arch Dermatol Res 281: 427-432, 1989.
33. Matsuo S, Penney NS, Fine JD, Gay S, and Nadjji M: A monoclonal antibody which identifies an antigen in endothelial cell and epithelial basement membrane. Blood Vessels 27 (1): 14-23, 1990.
34. Vaidya S, Tying SK, Feldcamp M, Johnson L, and Fine JD: HLA and epidermolysis bullosa: evidence for independent assortment of Weber-Cockayne subtype of epidermolysis bullosa and HLA complex. J Dermatol Science 2: 155-160, 1991.
35. Vaidya S, Tying SK, Johnson L, Fine JD: HLA and epidermolysis bullosa: association between the HLA complex and recessive dystrophic epidermolysis bullosa. Arch Dermatol 127: 1524-1527, 1991.
36. Fine JD, Horiguchi Y, Stein DH, Esterly NB, and Leigh IM: Intraepidermal type VII collagen: evidence for abnormal intracytoplasmic processing of a major basement membrane protein in rare patients with dominant and possibly localized recessive forms of dystrophic epidermolysis bullosa. J Am Acad Dermatol 22: 188-195, 1990.
37. McCarthy KJ, Horiguchi Y, Couchman JR, and Fine JD: Ultrastructural localization of the core protein of a basement membrane-specific chondroitin sulfate proteoglycan in adult rat skin. Arch Dermatol Res 282: 397-401, 1990.

38. Caldwell-Brown D, Stern RS, Lin AN, Carter DM, and the Epidermolysis Bullosa Study Group: Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. N Engl J Med 327: 163-167, 1992.
39. Horiguchi Y, Fine JD, and Couchman JR: Human skin basement membrane-associated heparan sulfate proteoglycan: distinctive differences in ultrastructural localization as a function of developmental age. Br J Dermatol 124: 410-414, 1991.
40. Horiguchi Y, Abrahamson D, and Fine J-D: Epitope mapping of the laminin molecule in murine skin basement membrane zone: demonstration of spatial differences in ultrastructural localization. J Invest Dermatol 96: 309-313, 1991.
41. Fine JD: 19-DEJ-1, a monoclonal antibody to the hemidesmosome-anchoring filament complex, is the only reliable immunohistochemical probe for all major forms of junctional epidermolysis bullosa. Arch Dermatol 126: 1187-1190, 1990.
42. Wright JT, Childers NK, Evans KL, Johnson LB, and Fine JD: Salivary function of individuals with hereditary epidermolysis bullosa. Oral Surgery, Oral Medicine, Oral Pathology 71: 553-559, 1991.
43. Schofield OMV, Fine JD, Pisani A, Heagerty AHM, Ortonne JP, and Eady RAJ: GB3 monoclonal antibody for the diagnosis of junctional epidermolysis bullosa: results of a multicentre study. J Am Acad Dermatol 23: 1078-1083, 1990.
44. Fine JD, Johnson LB, and Wright, T: Type VII collagen and 19-DEJ-1 antigen: comparison of expression in inversa and generalized variants of recessive dystrophic epidermolysis bullosa. Arch Dermatol 126: 1587-1593, 1990.
45. Chopra V, Tying SK, Johnson L, and Fine JD: Patients with severe forms of inherited epidermolysis bullosa exhibit decreased lymphokine and monokine production. J Clin Immunol 10: 321-329, 1990.
46. Shulman LP, Elias S, Andersen RN, Phillips OP, Milunsky A, Holbrook K, Smith L, Fine J-D, Simpson JL: Alpha-fetoprotein and acetylcholinesterase are not predictive of fetal junctional epidermolysis bullosa. Prenatal Diagnosis 11: 813-818, 1991.
47. Chopra V, Tying SK, Johnson LB, Fine J-D: Peripheral blood mononuclear cell subsets in patients with severe inherited forms of epidermolysis bullosa. Arch Dermatol 128: 201-209, 1992.
48. Horiguchi Y, Fine J-D, Leigh IM, Engvall E, Yoshiki T, Ueda M, Imamura S: Lamina densa malformation involved in histogenesis of primary localized cutaneous amyloidosis. J Invest Dermatol 99: 12-18, 1992.
49. Chan LS, Fine J-D, Briggaman RA, Woodley DT, Hammerberg C, Drugge RJ, Cooper KD: Identification and partial characterization of a novel 105-kilodalton lower lamina lucida autoantigen associated with a novel immune-mediated subepidermal blistering disease. J Invest Dermatol 101: 262-267, 1993.
50. Jennison M, Fine J-D, Gammon WR, O'Keefe EJ: Normal molecular weight of type VII collagen produced by recessive dystrophic epidermolysis bullosa fibroblasts. J Invest Dermatol 100: 93-96, 1993.
51. Wright JT, Fine J-D, Johnson LB: Hereditary epidermolysis bullosa: oral manifestations and dental management. Pediatr Dent 15: 242-248, 1993.
52. Wright JT, Fine J-D, Johnson LB: Dental caries risk in hereditary epidermolysis bullosa. Pediatr Dent 16: 427-432, 1994.
53. Wright JT, Johnson LB, Fine J-D: Developmental defects of enamel in humans with hereditary epidermolysis bullosa. Arch Oral Biol 38: 945-955, 1993.
54. Fine J-D, Johnson LB, Cronce D, Leigh IM, McCollough M, and Briggaman RA: Intracytoplasmic retention of type VII collagen and dominant dystrophic epidermolysis bullosa: reversal of defect following cessation of or marked improvement in disease activity. J Invest Dermatol 101: 232-236, 1993.
55. Chan Y-M, Yu Q-C, Fine J-D, Fuchs E: The genetic basis of Weber-Cockayne epidermolysis bullosa simplex. Proceedings of the National Academy of Sciences (USA) 90: 7414-7418, 1993.
56. Horiguchi Y, Maruguchi T, Maruguchi Y, Suzuki S, Fine J-D, Leigh IM, Yoshiki T, Ueda M, Toda K-I, Isshiki N, Imamura S: Ultrastructural and immunohistochemical characterization of basal cells in three-dimensional culture models of the skin. Arch Dermatol Res 286: 53-61, 1994.

57. McGrath JA, Ishida-Yamamoto A, Shimizu H, [Fine J-D](#), Eady RAJ: Immunoelectron microscopy of skin basement membrane zone antigens: a pre-embedding method using 1-nm immunogold with silver enhancement. [Acta Derm Venereol \(Stockh\)](#) 74: 197-200, 1994.
58. Chan LS, [Fine J-D](#), Hammerberg C, Bauer EA, Cooper KD: Defective in vivo expression and apparently normal in vitro expression of a newly identified 105-kDa lower lamina lucida protein in dystrophic epidermolysis bullosa. [Br J Dermatol](#) 132: 725-729, 1995.
59. Christiano AM, [Fine J-D](#), Uitto J: Genetic basis of dominantly inherited transient bullous dermolysis of the newborn: a splice site mutation in the type VII collagen gene. [J Invest Dermatol](#) 109: 811-814, 1997.
60. Wright JT, Hall KI, Deaton T, [Fine J-D](#): Structural and compositional alteration of tooth enamel in hereditary epidermolysis bullosa. [Connect Tissue Res](#) 34: 271-279, 1996.
61. Shimizu H, Sata M, Ban M, Kitajima Y, Ishizaki J, Harada T, Bruckner-Tuderman L, [Fine J-D](#), Burgeson R, Kon A, McGrath JA, Uitto J, Nishikawa T: Immunohistochemical, ultrastructural, and molecular features of Kindler's syndrome distinguish it from dystrophic epidermolysis bullosa. [Arch Dermatol](#) 133: 1111-1117, 1997.
62. Olivry T, Poujade-Delverdier A, Dunston SM, [Fine J-D](#), Ortonne J-P: Absent expression of collagen XVII (BPAG2, BP180) in canine familial localized junctional epidermolysis bullosa. [Vet Dermatol](#) 8: 203-212, 1997.
63. Uttam J, Hutton E, Coulombe P, Anton-Lamprecht I, Y Q-C, Gedde-Dahl T Jr, [Fine J-D](#), Fuchs E: The genetic basis of epidermolysis bullosa simplex with mottled pigmentation. [Proceedings of the National Academy of Sciences \(USA\)](#) 93: 9079-9084, 1996.
64. Olivry T, [Fine J-D](#), Dunston SM, Chasse D, Tenorio AP, Monteiro-Riviere NA, Chen M, Woodley DT: Canine epidermolysis bullosa acquisita: circulating autoantibodies target the aminoterminal noncollagenous (NC-1) domain of collagen VII in anchoring fibrils. [Vet Dermatol](#) 9: 19-31, 1998.
65. Zhang Z, [Fine J-D](#), Monteiro-Riviere NA: Uncenn may be a potential target for sulfur mustard alkylation. [Toxicology Report](#) 8: 27-36, 1998.
66. Arbisser JL, [Fine J-D](#), Murrell D, Paller A, Connors S, Keough K, Marsh E, Folkman J: Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. [Molecular Medicine](#) 4: 191-195, 1998.
67. [Fine JD](#), Johnson LB, Suchindran C, Moshell A, Gedde-Dahl T: The epidemiology of inherited EB: findings within American, Canadian, and European study populations. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 101-113.
68. [Fine JD](#), Johnson LB, Suchindran C, Bauer EA, Carter DM, McGuire J, Lin AN, Stern R, Nall L, Moshell A: Cutaneous and skin-associated musculoskeletal manifestations of inherited EB: the NEBR experience. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 114-146.
69. [Fine JD](#), Johnson LB, Suchindran C, Bauer EA, Carter DM, McGuire J, Lin AN, Stern R, Nall L, Moshell A: Extracutaneous features of inherited EB: the NEBR experience. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 147-174.
70. [Fine JD](#), Johnson LB, Suchindran C, Bauer EA, Carter DM, McGuire J, Lin AN, Stern R, Nall L, Moshell A: Cancer and inherited EB: the NEBR experience. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 175-192.
71. [Fine JD](#), Johnson LB, Moshell A, Suchindran C: Risk of selected major extracutaneous outcomes in inherited EB: life-table analyses of the NEBR study population. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 193-205.

72. [Fine JD](#), Johnson LB, Suchindran C, Bauer EA, Carter DM, McGuire J, Moshell A: Premature death and inherited EB: contingency table and lifetable analyses of the NEBR study population. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 206-224.
73. [Fine JD](#), Johnson LB, Suchindran C, Bauer EA, Carter DM, McGuire J, Lin AN, Stern R, Nall L, Moshell A: Socioeconomic features of inherited EB: the NEBR experience. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 257-279.
74. Pfender E, Uitto J, [Fine J-D](#): Epidermolysis bullosa carrier frequencies in the US population. [J Invest Dermatol](#) 116: 483-484, 2001.
75. Martinez-Mir A, Liu J, Gordon D, Weiner MS, Ahmad W, [Fine JD](#), Ott J, Gilliam TC, Christiano AM: EB simplex superficialis resulting from a mutation in the type VII collagen gene. [J Invest Dermatol](#) 118: 547-549, 2002.
76. Siegel DH, Ashton GHS, Penagos HG, Lee JV, Feiler HS, Wilhelmson KC, South AP, Smith FJ, Prescott AR, Wessagowit V, Oyama N, Akiyama M, Aboud, DA, Aboud KA, Githami AA, Hawsawi KA, Ismaili AA, Al-Suwaid R, Atherton DJ, Caputo R, [Fine J-D](#), Frieden IJ, Fuchs E, Haber RM, Harada T, Kitajima Y, Mallory SB, Ogawa H, Sahin S, Shimizu H, Suga Y, Tadini G, Tsuchiya K, Wiebe CB, Wojnarowska F, Zaghloul AB, Hamada T, Mallipeddi R, Eady RAJ, McLean WHI, McGrath JA, Epstein EH Jr: Loss of kindlin-1, a human homolog of the *C. elegans* actin-extracellular matrix linker protein UNC-112, causes Kindler syndrome. [Am J Hum Genet](#) 73: 174-187, 2003.
77. [Fine JD](#), Johnson LB, Weiner M, Stein A, Suchindran C: Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase I trial of systemic isotretinoin. [J Am Acad Dermatol](#) 50(4): 563-571, 2004.
78. Weiner M, Stein A, Cash S, DeLeoz J, [Fine JD](#): Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial. [Br J Dermatol](#) 150(3): 613-614, 2004.
79. Devries DT, Johnson LB, Weiner M, [Fine J-D](#): Relative extent of skin involvement in inherited epidermolysis bullosa (EB): composite regional anatomic diagrams based on the findings of the National EB Registry, 1986-2002. [J Am Acad Dermatol](#) 50(4): 572-581, 2004.
80. [Fine J-D](#), Johnson LB, Weiner M, Suchindran C: Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. [Clin Exp Dermatol](#) 29(2): 122-127, 2004.
81. [Fine J-D](#), Johnson LB, Weiner M, Stein A, Cash S, DeLeoz J, Devries DT, Suchindran C: Inherited epidermolysis bullosa (EB) and the risk of death from renal disease: experience of the National EB Registry [Am J Kidney Dis](#) 44 (4): 651-660, 2004.
82. [Fine J-D](#), Johnson LB, Weiner M, Stein A, Cash S, DeLeoz J, Devries DT, Suchindran C: Eye involvement in inherited epidermolysis bullosa (EB) : experience of the National EB Registry. [Am J Ophthalmol](#) 138 (2): 254-262, 2004.
83. [Fine J-D](#), Johnson LB, Weiner M, Stein A, Cash S, DeLeoz J, Devries DT, Suchindran C: Genitourinary complications of inherited epidermolysis bullosa (EB): experience of the National EB Registry and review of the literature. [J Urology](#) 172 (5 Pt 1): 2040-2044, 2004.
84. [Fine J-D](#), Johnson LB, Weiner M, Stein A, Cash S, DeLeoz J, Devries DT, Suchindran C: Pseudosyndactyly and musculoskeletal deformities in inherited epidermolysis bullosa (EB): experience of the National EB Registry, 1986-2002. [J Hand Surg \(British and European Volume\)](#) 30B (1): 14-22, 2005.
85. [Fine J-D](#), Johnson LB, Weiner M, Suchindran C: Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status, and family size. [Br J Dermatol](#) 152(5): 1009-1014, 2005.
86. [Fine J-D](#), Johnson LB, Weiner M, Li K-P, Suchindran C: Inherited epidermolysis bullosa (EB) and the risk of life-threatening skin-derived cancers: experience of the National EB Registry, 1986-2006. [J Am Acad Dermatol](#) (2008); in press).
87. Keane F, [Fine J-D](#), Weiner M, Stein A, McGrath JA, Eady R: Osteopenia and osteoporosis in recessive dystrophic epidermolysis bullosa (RDEB): results of DEXA scans in 42 consecutively studied patients within the United Kingdom and United States. (submitted for publication)

88. Fine J-D, Johnson LB, Weiner M, Suchindran C: Inherited epidermolysis bullosa (EB) and the cost of health care in the United States: experience of the National EB Registry. (submitted for publication).
89. Fine J-D, Johnson LB, Weiner M, Suchindran C: Inherited epidermolysis bullosa and the American health care system: relative utilization of specialty versus primary care providers, inpatient versus outpatient care, and patient-parent satisfaction. (submitted for publication).
90. Fine J-D, Johnson LB, Weiner M, Suchindran C: Tracheolaryngeal complications of inherited epidermolysis bullosa: cumulative experience of the National EB Registry. *Laryngoscope* 117(9): 1652-1660, 2007.
91. Fine J-D, Johnson LB, Weiner M, Suchindran C: Gastrointestinal complications of inherited epidermolysis bullosa: cumulative experience of the National EB Registry. *J Ped Gastroenterol Nutr* 46(2): 147-158, 2008.
92. Fine J-D, Johnson LB, Weiner M, Suchindran C: Cause-specific risks of childhood death in inherited epidermolysis bullosa. *J Pediatr* 152(2): 276-280, 2008. [DOI: 10.1016/j.jpeds.2007.06.039].
93. Fine J-D, Hall M, Weiner M, Li K-P, Suchindran C: The risk of cardiomyopathy in inherited epidermolysis bullosa. *Br J Dermatol* (2008; in press).

**B. Review Articles, Book Chapters (excluding those containing peer-reviewed original research), and Consensus Reports**

1. Fine JD: Mastocytosis. Int J Dermatol 19: 117-123, 1980.
2. Fine JD and Arndt KA: Propylene glycol: a review. Excerpta Medica 1980.
3. Fine JD and Arndt KA: Seborrheic dermatitis. In *Clinical Dermatology* (edited by Demis DJ, Crounse RB, Dobson RL, and McGuire J), Hagerstown, Md., Harper and Row, Vol. 1, Unit 1-7, 1980.
4. Fine JD and Arndt KA: Lichen planus. In *Clinical Dermatology* (edited by Demis DJ, Crounse RB, Dobson RL, and McGuire J), Hagerstown, Md., Harper and Row, Vol. 1, Unit 1-9, 1980.
5. Fine JD and Arndt KA: Pityriasis rosea. In *Clinical Dermatology* (edited by Demis DJ, Crounse RB, Dobson RL, and McGuire J), Hagerstown, Md., Harper and Row, Vol. 1, Unit 1-14, 1980.
6. Fine JD and Arndt KA: Dry skin. In *Clinical Dermatology* (edited by Demis DJ, Crounse RB, Dobson RL, and McGuire J), Hagerstown, Md., Harper and Row, Vol. 1, Unit 1-19, 1980.
7. Fine JD and Arndt KA: Challenging case studies in infectious dermatoses III. Profiles in Practice No.9, 1981
8. Fine JD, Wise TG, and Falchuk KH: Zinc in cutaneous diseases and dermatologic therapeutics. In *Dermatology Update - Reviews for Physicians* (Editor-in-Chief: Moschella SL), New York, Elsevier, pp. 299-312, 1982.
9. Fine JD and Arndt KA: Topical therapy: a dermatologic formulary for pediatric practice. In *Current Pediatric Therapy* (edited by Gellis SS and Kagan BM), 10th ed., Philadelphia, W.B. Saunders, pp. 425-431, 1982.
10. Fine JD: Systemic mastocytosis. N Engl Soc Allergy Proc 3: 244-248, 1982.
11. Fine JD and Arndt KA: Topical therapy: a dermatologic formulary for pediatric practice. In *Current Pediatric Therapy* (edited by Gellis SS and Kagan BM), 11th ed., Philadelphia, W.B. Saunders, pp. 425-432, 1984.
12. Arndt KA and Fine JD: Drugs in dermatologic therapy. In *Drugs of Choice 1984 - 1985* (edited by Modell W), St. Louis, Mosby, pp. 738-750, 1984.
13. Fine JD and Arndt KA: TORCH syndrome. In *Clinical Dermatology* (edited by Demis DJ, Crounse RG, Dobson RL, and McGuire J), Hagerstown, Md., Harper and Row, Vol. 4, Unit 31-2, 1984.
14. Fine JD and Arndt KA: Pathophysiology of certain viral diseases. In *Pathophysiology of Dermatologic Diseases* (edited by Soter NA and Baden HP), New York, McGraw-Hill, pp. 360-375, 1984.
15. Fine JD: The use of monoclonal antibodies in skin basement membrane research. Collagen Rel Res 4: 75-81, 1984.
16. Fine JD and Moschella SL: Nutrition and metabolism. In *Dermatology* (edited by Moschella SL and Hurley HJ, Jr), 2nd ed., Philadelphia, W.B. Saunders, 1985, pp. 1422-1532.
17. Fine JD and Arndt KA: The TORCH syndrome: a clinical review. J Am Acad Dermatol 12: 697-706, 1985.
18. Fine JD: Monoclonal antibodies and the skin biopsy: current and potential clinical applications. Am J Med Sci 290: 143-151, 1985.
19. Fine JD: Introduction to the vesiculobullous diseases. In *Clinical Dermatology* (edited by Demis DJ, Dobson RL, McGuire J), Hagerstown, Md, Unit 6-0, 1986, pp. 1-10.
20. Fine JD and Arndt KA: Topical therapy: a dermatologic formulary for pediatric practice. In *Current Pediatric Therapy* (edited by Gellis SS and Kagan BM), 12th ed., Philadelphia, W.B. Saunders, 1986, pp. 441-448.
21. Fine JD: Epidermolysis bullosa: clinical aspects, pathology, and recent advances in research. Int J Dermatol 25: 143-157, 1986.
22. Fine JD: The skin basement membrane zone. In *Advances in Dermatology* Volume 2, (ed by J Callen), Chicago, Year Book Publishers, 1986, pp. 283-303.

23. Fine JD: Altered skin basement membrane antigenicity in epidermolysis bullosa. In *Biology of Heritable Skin Diseases* (ed. by KD Wuepper & T Gedde-Dahl Jr), Basel, Karger. Curr Prob Dermatol 17: 111-126, 1987.
24. Fine JD, Hintner H, and Katz SI: Immunofluorescence studies in epidermolysis bullosa utilizing polyclonal and monoclonal antibodies. In *Immunopathology of the Skin* (edited by Beutner EH, Chorzelski TP, Kumar V), 3rd edition, New York, John Wiley & Sons, Inc., 1987, pp. 399-405.
25. Gay S and Fine JD: Immunization, isolation and characterization of poly- and monoclonal antibodies against collagen for use in immuno-histochemistry. *Methods Enzymol* 145: 148-167, 1987.
- 26a & b. Fine JD: Skin diseases of pregnancy. In *Conn's Current Therapy* (ed. by Rakel RE), 39th ed., Philadelphia, WB Saunders Co., 1987, pp. 698-699, and 40th ed., 1989, pp. 756-757.
27. Spiers EM and Fine JD: Immunopathogenesis of bullous diseases. In *Clinical Dermatology* (Demis DJ, chief editor), Philadelphia, Harper & Row, 1987, Unit 6-1, pp. 1-29.
28. Fine JD: Epidermolysis bullosa. In *Common Problems in Dermatology: Recommendations of the Experts* (ed. by Greer KE), Chicago, Year Book Publishers, 1987, pp. 110-119.
29. Fine JD: Common office dermatoses: approach to diagnosis and therapy. Alabama J Med Sci 24: 209-215, 1987.
30. Fine JD: Clinical and diagnostic aspects of inherited epidermolysis bullosa. Curr Concepts in Skin Disorders 8(3): 5-11, 1987.
31. Fine JD: Cicatricial and localized pemphigoid. In *Immunologic Diseases of the Skin* (RE Jordon, ed.), East Norwalk, CT, Appleton-Century-Crofts, 1991, pp. 303-313.
32. Fine JD: Cicatricial pemphigoid. In *The Management of Blistering Diseases*, (ed. by F Wojnarowska and RA Briggman), Chapman & Hall Ltd, London, 1990, pp. 83-92.
33. Fine JD, Brooke P, and Moschella SL: Diseases of nutrition and metabolism. In *Clinical Dermatology* (edited by Orkin M, Maibach HI, & Dahl MV), New York, Appleton-Lange, 1991, pp. 374-392.
34. Fine JD and Arndt KA: Medical dermatologic therapy. In *Clinical Dermatology* (edited by Orkin M, Maibach HI, & Dahl MV), New York, Appleton-Lange, 1991, pp. 635-656.
35. Fine JD: The skin and endocrine disorders. In *Principles and Practice of Endocrinology and Metabolism* (ed. by Becker KL), Philadelphia, JB Lippincott, 1990, pp. 1598-1607.
36. Fine JD: Antigenic features and structural correlates of basement membranes: relationship to epidermolysis bullosa. Arch Dermatol 124: 713-717, 1988.
37. Fine JD: Changing clinical and laboratory concepts in inherited epidermolysis bullosa. Arch Dermatol 124: 523-526, 1988.
38. Fine JD: Pathology and pathogenesis of epidermolysis bullosa. In *Epidermolysis Bullosa, Basic and Clinical Aspects* (ed. by DM Carter & AN Lin), Springer-Verlag, 1992, pp. 37-62.
39. Fine JD: Hereditary bullous disorders. In *Genetic Disorders of the Skin* (ed. by JC Alper), Year Book Medical Publishers, Chicago, 1991, pp. 124-143.
40. Fine JD: Immunobullous diseases. In *Principles and Practice of Dermatology* (ed. by WM Sams Jr & PJ Lynch), New York, Churchill Livingstone, 1990, pp. 419-437.
41. Fine JD: Mechanical and other blistering diseases. In *Principles and Practice of Dermatology* (ed. by WM Sams Jr & PJ Lynch), New York, Churchill Livingstone, 1990, pp. 439-443.
42. Fine JD and Arndt KA: Topical therapy: a dermatologic formulary for pediatric practice. In *Current Pediatric Therapy* (edited by Gellis SS and Kagan BM), 13th ed., Philadelphia, W.B. Saunders, 1990, 421-428.
43. Fine JD: Basement membrane-related antigens: their significance in epidermolysis bullosa. In *Epidermolysis Bullosa: A Comprehensive Review of Classification, Management and Laboratory Studies* (ed. by GC Priestley, MJ Tidman, JB Weiss, & RAJ Eady), Berkshire UK, DEBRA Publications, 1990, 40-49.

44. Fine JD: Recent clinical studies in inherited epidermolysis bullosa. In *Epidermolysis Bullosa: A Comprehensive Review of Classification, Management and Laboratory Studies* (ed. by GC Priestley, MJ Tidman, JB Weiss, & RAJ Eady), Berkshire UK, DEBRA Publications, 1990, 186-190.
45. Sontheimer RD and Fine JD: Biology of the dermoepidermal interface and the pathophysiology of bullous pemphigoid, epidermolysis bullosa acquisita, and lupus erythematosus. In *Pathophysiology of Dermatologic Diseases* (ed. by NA Soter & HP Baden), 2nd edition, New York, McGraw-Hill, 1991, pp. 303-325.
46. Fine JD: Epidermolysis bullosa. In *Clinical Dermatology* (Demis DJ, chief editor), Philadelphia, Harper & Row, 1991, Unit 6-6, pp. 1-31.
47. Fine JD, Bauer EA, Briggaman RA, Carter DM, Eady RAJ, Esterly NB, Holbrook KA, Hurwitz S, Johnson L, Lin A, Pearson R, and Sybert VP: Revised clinical and laboratory criteria for subtypes of inherited epidermolysis bullosa: a consensus report by the Subcommittee on Diagnosis and Classification of the National Epidermolysis Bullosa Registry. *J Am Acad Dermatol* 24: 119-135, 1991.
48. Couchman JR, McCarthy KJ, Abrahamson DR, Fine JD, and Parry G: Immunological and molecular approaches to the study of basement membrane proteoglycan diversity. *Biochem Soc Trans* 18: 819-820, 1990.
49. Fine JD: Bullous Diseases. In *Dermatology* (ed. by SL Moschella & HJ Hurley), 3rd edition, Philadelphia, WB Saunders Co., 1992, pp. 655-697.
50. Fine JD and Horiguchi Y: Immunoelectron microscopy and immunofluorescence antigenic mapping: diagnostic applications. *Clinics in Dermatology* 9: 179-185, 1991.
51. Fine JD, Johnson LB, and Wright JT: Inherited blistering diseases of the skin. *Pediatrician* 18 (3): 175-187, 1991.
52. Fine JD: Structure and antigenicity of the skin basement membrane zone. *J Cutan Pathol* 18: 401-409, 1991.
53. Fine JD, Guest P: Dermatology. In *Cecil Review of General Internal Medicine*, 5th edition, New York, McGraw-Hill, 1992, pp. 240-251.
54. Gammon WR, Fine JD, Forbes M, Briggaman RA: Immunofluorescence on split skin for the detection and differentiation of BMZ autoantibodies. *J Am Acad Dermatol* 27: 79-87, 1992.
55. Wright JT, Fine JD: Oral manifestations in hereditary epidermolysis bullosa. *Seminars in Dermatology* 13(2): 102-107, 1994.
56. Fine JD: Basement Membrane Proteins. In *The Keratinocyte Handbook*, Cambridge University Press (IM Leigh, EB Lane, & FM Watt, editors), Cambridge, 1994, pp 181-199.
57. Fine JD, Briggaman RA, Gammon WR: The Laboratory Approach to the Evaluation of Vesiculobullous Disorders. In *Bullous Diseases* (JD Fine, editor) (in Topics in Clinical Dermatology series), Igaku-Shoin Medical Publishers, New York / Tokyo, 1993, pp 3-22.
58. Fine JD: Inherited epidermolysis bullosa. In *Bullous Diseases* (JD Fine, editor) (in Topics in Clinical Dermatology series), Igaku-Shoin Medical Publishers, New York / Tokyo, 1993, pp 135-162.
59. Gammon WR, Fine JD, Briggaman RA: Autoimmunity to type VII collagen: features and role in basement membrane injury. In *Bullous Diseases* (JD Fine, editor) (in Topics in Clinical Dermatology series), Igaku-Shoin Medical Publishers, New York / Tokyo, 1993, pp 75-96.
60. Fine JD: Laboratory tests in epidermolysis bullosa. *Dermatologic Clinics* 12 (1): 123-132, 1994.
61. Meyer DJ, Fine JD, Smith EB: Seborrheic dermatitis. In *Clinical Dermatology* (Demis DJ, chief editor), Philadelphia, Harper & Row, 1993, Unit 1-7.
62. Fine JD, Johnson LB, Suchindran CM: The National Epidermolysis Bullosa Registry. *J Invest Dermatol* 102: 54S-56S, 1994.
63. Wright JT, Fine JD: The ectodermal dysplasias. In *Cutaneous Medicine and Surgery* (ed. by Arndt KA, Leboit PE, Robinson JK, Wintrob BU), Philadelphia, WB Saunders, 1996, pp. 1721-1724.



64. Fine JD, Guest PJ: Papulosquamous disorders. In *Current Pediatric Therapy* (ed. by Burg FD, Ingelfinger JR, Wald ER, Polin RA), 15 edition, Philadelphia, WB Saunders, 1996, pp. 521-524.
65. Fine JD, Resnick SD: Vesiculobullous and neonatal pustular diseases. In *Pediatric Dermatology* (ed. by Schachner LA, Hansen, RC), 2nd edition, New York, Churchill Livingstone, 1995, pp. 767-809.
66. Fine JD, Spiers EM: Bullous Diseases. In *Cutaneous Medicine and Surgery: An Integrated Program in Dermatology. Self-Assessment and Review.* (ed. by Dover JS), Philadelphia, WB Saunders Company, 1996, pp. 144-156.
67. Fine JD, Wright JT: Epidermolysis bullosa. In *Clinical Dermatology* (Demis DJ, chief editor), Philadelphia, Harper & Row, Unit 6-6, 1995, pp. 1-35.
68. Becker KL, Fine JD: The skin and endocrine disorders. In *Principles and Practice of Endocrinology and Metabolism* (ed. by Becker KL), 2nd edition, Philadelphia, JB Lippincott, 1995, pp. 1830-1840.
69. Fine JD: Epidermolysis bullosa. In *Cutaneous Medicine and Surgery* (ed. by Arndt KA, Leboit PE, Robinson JK, Wintroub BU), Philadelphia, WB Saunders, 1996, pp. 635-650.
70. Fine JD, Fuchs EV: The science of the dermoepidermal junction: structure, biochemistry, antigenicity, and recent molecular biological studies. In *Cutaneous Medicine and Surgery* (ed. by Arndt KA, Leboit PE, Robinson JK, Wintroub BU), Philadelphia, WB Saunders, 1996, pp. 617-634.
71. Fine JD: Immunobullous diseases. In *Principles and Practice of Dermatology* (ed. by WM Sams Jr & PJ Lynch), 2nd edition, New York, Churchill Livingstone, 1996, pp. 455-473.
72. Fine JD: Mechanical and other blistering diseases. In *Principles and Practice of Dermatology* (ed. by WM Sams Jr & PJ Lynch), 2nd edition, New York, Churchill Livingstone, 1996, pp. 475-481.
73. Fine JD: Epidermolysis bullosa: application of epidemiological principles to the study of a group of rare diseases via a disease registry. Dermatologic Clinics 13: 659-670, 1995.
74. Fine JD: International symposium on epidermolysis bullosa. J Invest Dermatol 103: 839-843, 1994.
75. Arbiser J, Fine JD, and Arndt KA: Other viral infections. In *The Skin in Infection: A Color Atlas and Text* (ed. by Sanders CV & Nesbitt LT Jr), Baltimore, Williams & Wilkins, 1995, pp 200-206.
76. Fine JD: Management of acquired bullous skin diseases. N Engl J Med 333: 1475-1484, 1995.
77. Fine JD: Epidemiology and the study of genetic diseases. In *Epidemiology and Prevention of Skin Diseases* (ed. by Grob JJ, Stern RS, MacKie RM, & Weinstock MA), Oxford UK, Blackwell Science, Ltd., 1997, pp. 32-38.
78. Fine JD: Bullous diseases. In *Conn's Current Therapy* (ed. by Rakel RE), Philadelphia, WB Saunders, 1997, pp. 851-856.
79. Fine JD: Introduction to vesiculobullous diseases. In *Clinical Dermatology* (Demis DJ, chief editor), Philadelphia, Harper & Row, Unit 6-0, 1997.
80. Fine JD: Rare disease registries -- lessons learned from the National Epidermolysis Bullosa Registry. J Rare Diseases 2 (5): 5-14, 1996.
81. Fine JD, Bauer EA, Gedde-Dahl T: Inherited epidermolysis bullosa: definition and historical overview. In Fine JD (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 1-19.
82. Fine JD: Classification of inherited epidermolysis bullosa: current approach, pitfalls, unanswered questions, and future directions. In Fine JD (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 20-47.

83. [Fine JD](#), Smith LT: Non-molecular diagnostic testing of inherited epidermolysis bullosa: current techniques, major findings, and relative sensitivity and specificity. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 48-78.
84. [Fine JD](#), Johnson LB, Suchindran C, Carter DM, Moshell A: The National Epidermolysis Bullosa Registry (NEBR): organization, goals, methodologic approaches, basic demography, and accomplishments. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 79-100.
85. [Fine JD](#), McGuire J: Altered nutrition and inherited EB. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 225-235.
86. Holbrook KA, [Fine JD](#), Elias S, Christiano AM: Prenatal diagnosis of inherited EB: ultrastructural, antigenic, and molecular approaches. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 351-373.
87. [Fine JD](#), Bauer EA, McGuire J: The treatment of inherited epidermolysis bullosa: nonmolecular approaches. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 374-406.
88. Gammon WR, [Fine JD](#), Briggaman RA: Epidermolysis bullosa acquisita. In [Fine JD](#) (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*, Baltimore, Johns Hopkins University Press, 1999, pp. 420-444.
89. Weber DJ, Cohen MS, [Fine J-D](#): The acutely ill patient with fever and rash. In [Mandell GL](#), [Bennett JE](#), and [Dolin R](#), 5th edition, New York, Churchill Livingstone, 2000, pp. 633-650.
90. Becker KL, Nasir A, [Fine JD](#): The skin and endocrine disorders. In [Principles and Practice of Endocrinology and Metabolism](#) (ed. by Becker KL), 3rd edition, Philadelphia, JB Lippincott, 1998.
91. [Fine J-D](#), Eady RAJ, Bauer EA, Briggaman RA, Bruckner-Tuderman L, Christiano A, Heagerty A, Hintner H, Jonkman M, McGrath J, McGuire J, Moshell A, Shimizu H, Tadini G, Uitto J: Revised Classification System for Inherited Epidermolysis Bullosa: Report of the Second International Consensus Meeting on Diagnosis and Classification of Epidermolysis Bullosa. [J Amer Acad Dermatol](#) 42: 1051-1066, 2000.
92. Uitto J, Eady R, [Fine J-D](#), Dart J: The DebRA international visioning / consensus meeting on epidermolysis bullosa: summary and recommendations. [J Invest Dermatol](#) 114: 734-737, 2000.
93. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, [Fine J-D](#), Foster CS, Ghohestani R, Hashimoto T, Hoang-Xuan T, Kirtschig G, Korman NJ, Lightman S, Lozada-Nur F, Marinkovich P, Mondino BJ, Prost-Squarcioni C, Rogers RS, Setterfield JF, West D, Wojnarowska F, Woodley DT, Yancey KB, Zillikens D, Zone J: The first consensus statement on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic factors. [Arch Dermatol](#) 138: 370-379, 2002.
94. Morrell D, [Fine J-D](#): Papulosquamous Diseases. In [Current Pediatric Therapy](#) (ed. by Burg FD, Ingelfinger J, Polin RA, Gershon A), 17th edition, Philadelphia, WB Saunders, 2002, pp. 865-867.
95. [Fine JD](#): Epidermolysis bullosa simplex. In [The NORD Guide to Rare Diseases](#), Philadelphia, Lippincott, Williams, & Wilkins, 2003, pp. 108-109.
96. [Fine JD](#): Junctional epidermolysis bullosa. In [The NORD Guide to Rare Diseases](#), Philadelphia, Lippincott, Williams, & Wilkins, 2003, pp. 107-108.
97. [Fine JD](#): Dystrophic epidermolysis bullosa. In [The NORD Guide to Rare Diseases](#), Philadelphia, Lippincott, Williams, & Wilkins, 2003, pp. 106-107.

98. Fine JD: Inherited epidermolysis bullosa: a genetic paradigm for chronically abnormal wound healing. *Textbook of Wound Repair* (ed. by RAF Clark), Philadelphia, WB Saunders, 2001 (in press).
99. Fine JD: Blistering Diseases. In *Dermatology - Just the Facts* (ed. by FA Kerdel and F Jimenez-Acosta), New York, McGraw-Hill, 2003, pp. 129-147.
100. Fine JD: Epidermolysis bullosa. In *Dermatology* (ed. by JL Bolognia, JL Jorizzo, RR Rapini et al), 1st edition, London, Harcourt Health Sciences, 2003, pp. 491-500.
101. Eady RAJ, Fine J-D, Burge SM. Genetic blistering diseases. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. *Rook's Textbook of Dermatology*. 7th edition. Oxford, Blackwell Science, 2004:40.1-40.32.
102. Fine JD: Life expectancy and outcome measurements. In *Proceedings of a Multidisciplinary International Symposium on the Clinical Management of Children and Adults with Epidermolysis Bullosa* (ed. by J Mellerio and D Atherton), London, DEBRA-UK, 2004.
103. Fine JD: Epidemiology of urogenital problems in EB. In *Proceedings of a Multidisciplinary International Symposium on the Clinical Management of Children and Adults with Epidermolysis Bullosa* (ed. by J Mellerio and D Atherton), London, DEBRA-UK, 2004.
104. Fine J-D: Epidermolysis bullosa: a genetic disease of altered cell adhesion and wound healing, and the possible clinical utility of topically applied thymosin  $\beta_4$ . *Ann NY Acad Sci* 1112: 296-406, 2007.
105. Fine JD: Epidermolysis bullosa. In *Dermatology* (ed. by JL Bolognia, JL Jorizzo, RR Rapini et al), 2nd edition, London, Elsevier Science Ltd, 2008, pp. 457-466.
106. Fine J-D, Burge SM. Genetic blistering diseases. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. *Rook's Textbook of Dermatology*. 8th edition. Oxford, Blackwell Science (in press, 2007).
107. Fine J-D, Eady RAJ, Bauer EA, Bauer J, Bruckner-Tuderman L, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, McGrath J, Mellerio JE, Murrell DF, Shimizu H, Uitto J, Vahlquist A, Woodley D, Zambunato G: The Classification of Inherited Epidermolysis: Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. *J Am Acad Dermatol* 58(6): 931-950, 2008.
108. Fine JD: Epidermolysis bullosa. BMJ Publishing Group BMJ In-Practice software program (2008). [a peer reviewed project by the Br Med J, linked with Epocrates drug database]
109. Fine JD, Mellerio J: Extracutaneous manifestations or complications of inherited epidermolysis bullosa. *J Am Acad Dermatol* (submitted 2008).
110. Fine JD: Internal complications. In: Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press).
111. Landschuetzer, C, Fine JD: Classification and molecular basis of hereditary epidermolysis bullosa. In: Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press)
112. Fine JD: Epidemiology of EB. In: Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press)
113. Fine JD: General cutaneous manifestations. In: Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press)
114. Fine JD, Landschuetzer C: Cancer and epidermolysis bullosa. In: Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press)
115. Fine JD: Musculoskeletal deformities In: Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press)

116. Fine JD: Premature death in EB. In: Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press)
117. Fine JD: Psychological and sociological aspects. In: Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press)
118. Fine JD: Surveillance for extracutaneous complications In: Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press)

**C. Clinical Series, Case Reports, Invited Editorials, and Miscellaneous Publications**

1. Fine JD, Luke RG, and Rees ED: Multiple myeloma and renal impairment (Letter to the Editor). Lancet 2: 1205-1206, 1973.
2. Fine JD: Loeffler's syndrome? (Letter to the Editor). Arch Dermatol 115: 677, 1979.
3. Fine JD, Harrist TJ, Radford MJ, and Bradley A: Adult scalded skin syndrome fatally complicated by mixed gram negative sepsis and cellulitis. Cutis 27: 162-168, 1981.
4. Fine JD, Miller JA, Harrist TJ, and Haynes HA: Cutaneous lesions in disseminated candidiasis mimicking ecthyma gangrenosum. Am J Med 70: 1133-1135, 1981.
5. Case Records of the Massachusetts General Hospital: Case 13-1981. N Engl J Med 304: 773-774, 1981.
6. Fine JD and Harrist TJ: Cutaneous leukocytoclastic vasculitis in the rose spot of paratyphoid fever. Int J Dermatol 21: 216-217, 1982.
7. Harrist TJ, Fine JD, Berman RS, Murphy GF, and Mihm MC Jr: Neutrophilic eccrine hidradenitis: a distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol 118: 263-266, 1982.
8. Fine JD, Katz SI, Donahue MJ, and Hendricks AA: Psychiatric reaction to dapsone and sulfapyridine. J Am Acad Dermatol 9: 274-275, 1983.
9. Maturi MF, Fine JD, Schaffer EH, Minuk GY, and Hoofnagle JH: Pyoderma gangrenosum associated with primary biliary cirrhosis. Arch Int Med 143: 1261-1263, 1983.
10. Fine JD and Omura E: Herpes gestationis: persistent disease activity 11 years post-partum. Arch Dermatol 121: 924-926, 1985.
11. Fine JD, Osment LS, and Gay S: Dystrophic epidermolysis bullosa: a new variant characterized by progressive symmetrical centripetal involvement with scarring. Arch Dermatol 121: 1014-1017, 1985.
12. Barton DD, Fine JD, Gammon WR, and Sams WM Jr: Bullous systemic lupus erythematosus: an unusual clinical course and detectable circulating autoantibodies to the epidermolysis bullosa acquisita antigen. J Am Acad Dermatol 15: 369-373, 1986.
13. Fine JD and Breathnach SM: A distinctive eruption characterized by linear suppurative papules and erythroderma following bromodeoxyuridine (BUDR) and radiotherapy. Arch Dermatol 122: 199-200, 1986.
14. Fine JD: Epidermolysis bullosa controlled by vitamin E - reply (Response to Letter to the Editor). Int J Dermatol 25: 671, 1986.
15. Paller AS, Fine JD, Kaplan S, and Pearson RW: The generalized atrophic benign form of junctional epidermolysis bullosa: experience with four patients in the United States. Arch Dermatol 122: 704-710, 1986.
16. Rubenstein R, Esterly NB, and Fine JD: Childhood epidermolysis bullosa acquisita: detection in a five year old girl. Arch Dermatol 123: 772-776, 1987.
17. Jones CS, Tying SK, Lee PC, and Fine JD: Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in erythema ab igne. Arch Dermatol 124: 110-113, 1988.
18. Tying SK, Jones CS, Lee PC, and Fine JD: Development of verrucous plaques and gross hematuria in advanced cutaneous T cell lymphoma. Arch Dermatol 124: 655-657, 1988.
19. Forman AB, Prendiville JS, Esterly NB, Hebert AA, Duvic M, Horiguchi Y, and Fine JD: Kinder syndrome: report of two cases and review of the literature. Pediatric Dermatol 6: 91-101, 1989.
20. Fine JD, Stenn J, Johnson L, Wright T, Bock H-GO, and Horiguchi Y: Autosomal recessive epidermolysis bullosa simplex: generalized phenotypic features suggestive of junctional or dystrophic epidermolysis bullosa, and association with neuromuscular diseases. Arch Dermatol 125: 931-938, 1989.

21. Fine JD, Johnson L, and Wright T: Epidermolysis bullosa simplex superficialis: a new variant of epidermolysis bullosa characterized by subcorneal skin cleavage mimicking peeling skin syndrome. Arch Dermatol 125: 633-638, 1989.
22. Fine JD, Johnson L, Wright T, and Horiguchi Y: Epidermolysis bullosa simplex: identification of a kindred with autosomal recessive transmission of the Weber-Cockayne variety. Pediatr Dermatol 6: 1-5, 1989.
23. Fine JD, Johnson LB: Inherited epidermolysis bullosa in Croatia (Invited Editorial in Response to Accompanying Published Article). Pediatr Dermatol 7: 147-149, 1990.
24. Prendiville JS, Fine JD, Esterly NB: Kindler syndrome and epidermolysis bullosa simplex. J Am Acad Dermatol 23: 327-328, 1990.
25. Finley WH, Lindsey JR Jr, Fine JD, Dixon GA, Burbank MK: Autosomal dominant erythromelalgia. Am J Med Genetics 42: 310-315, 1992.
26. Horiguchi Y, Mitani T, Danno K, Ozaki M, Fine JD, Leigh IM, Imamura S: Extensive variant of cutaneous amyloidosis: report of a case with electron-microscopic and immunohistochemical studies of the basement membrane zone at sites of amyloid production. Dermatology 185: 181-189, 1992.
27. Wright JT, Fine JD, Johnson LB, Steinmetz TT: Oral involvement of recessive dystrophic epidermolysis bullosa inversa. Am J Med Genetics 47: 1184-1188, 1993.
28. Shimizu H, Fine J-D, Suzumori K, Hata N, Shozu M, Nishikawa T: Prenatal exclusion of pyloric atresia - junctional epidermolysis bullosa syndrome. J Am Acad Dermatol 31: 429-433, 1994.
29. Miller JL, Stricklin GP, Fine JD, King LE, Arzubiaga MC, Ellis DL: Successful treatment of severe resistant epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 133: 467-471, 1995.
30. Lin AN, Smith LT, Fine J-D: Dystrophic epidermolysis bullosa-inversa: report of two cases with further correlation between electron microscopic and immunofluorescence studies. J Am Acad Dermatol 33: 361-365, 1995.
31. Fine JD: Management of acquired bullous skin diseases (response to Letter to the Editor). N Engl J Med 334: 864-865, 1996.
32. Shaw DW, Fine J-D, Piacquadro DJ, Greenberg MJ, Wang-Rodriguez J, Eichenfield LF: Gastric outlet obstruction and epidermolysis bullosa. J Am Acad Dermatol 36: 304-310, 1997.
33. Jonkman MF, Pas HH, Fine JD: Mosaic expression of uncein, linear IgA dermatosis antigen and 180-kDa bullous pemphigoid antigen in generalized atrophic benign epidermolysis bullosa (Letter to the Editor). Br J Dermatol 138: 904, 1998.
34. Hanson SG, Fine J-D, Levy ML: Three new cases of transient bullous dermolysis of the newborn. J Am Acad Dermatol 40: 471-476, 1999.
35. Fine J-D, Eady RAJ: Tetracycline and epidermolysis bullosa simplex - a new indication for one of the oldest and widely used drugs in dermatology? (invited editorial) Arch Dermatol 135: 981-982, 1999.
36. Ghali FE, Stein LD, Fine J-D, Burkes EJ, McCauliffe DP: Gingival telangiectases: an underappreciated physical sign of juvenile dermatomyositis. Arch Dermatol 135: 1370-1374, 1999.
37. Ghali FE, Fine J-D: Idiopathic unilateral hyperhidrosis in a child. Pediatr Dermatol 17(1): 25-28, 2000.
38. Morrell D, Rubenstein D, Briggman R, Fine J-D, Pulkkinen L, Uitto J: Congenital pyloric atresia in a newborn with extensive aplasia cutis congenita and epidermolysis bullosa simplex. Br J Dermatol 143: 1342-1343, 2000.
39. Fine J-D, McGrath J, Eady RAJ: Inherited epidermolysis bullosa comes into the new millenium: a revised classification system based on current knowledge of pathogenetic mechanisms, and the clinical, laboratory, and epidemiological findings of large, well defined patient cohorts. (invited editorial) J Am Acad Dermatol 43: 135-137, 2000.
40. Fine J-D: Skin bioequivalents and their role in the treatment of inherited epidermolysis bullosa. (invited editorial) Arch Dermatol 136: 1259-1260, 2000.

41. Morrell D, [Fine J-D](#): Junctional epidermolysis bullosa with pyloric atresia (letter to the editor). [Ped Dermatol](#) 18(6): 539-540, 2001.
42. Friedman JS, Fulghum RA, Woosley J, [Fine J-D](#): A unique presentation of calcinosis cutis in a cystic fibrosis patient after double lung transplantation. [J Am Acad Dermatol](#) 49: 1131-1136, 2003.
43. [Fine J-D](#): Possible role of sentinel node biopsy in the management of squamous cell carcinomas in inherited epidermolysis bullosa (letter to the editor). [Arch Dermatol](#) 140: 1012-1013, 2004.
44. [Fine J-D](#): invited book review of *Warts: Diagnosis and Management – An Evidence-Based Approach* (edited by Brodell RT and Johnson SM), [N Engl J Med](#) 350(26): 2725, 2004.
45. [Fine J-D](#): Inherited epidermolysis bullosa registries. Whither hence? (invited editorial and review) [Giornale Italiano di Dermatologia e Venereologia](#) (G Ital Dermatol Venereol) 140: 309-313, 2005.
47. Rubin AL, Moran K, [Fine J-D](#), Wargon O, Murrell DF: Urethral meatal stenosis in junctional epidermolysis bullosa: a rare complication effectively treated with a novel and simple modality. [Int J Dermatol](#) 46: 1076-1077, 2007.

#### D. Selected Abstracts

1. Fine JD: Bence Jones aggregation and renal failure. Texas Reports Biol Med 31: 567, 1974.
2. Fine JD, Wasson S, and Rees ED: Role of Bence Jones protein in renal failure. Clin Res 22: 535A, 1974.
3. Fine JD, Breathnach SM, Fox PA, Neises GR, Stanley JR, and Katz SI: A unique primate and keratinocyte specific differentiation antigen defined by a monoclonal antibody. Clin Res 30(2): 261A, 1982.
4. Smith SB, Harrist TJ, Murphy GF, Halperin AJ, Fallon JT, Fine JD and Mihm MC Jr: The histologic differential diagnosis of linear IgA bullous dermatosis and dermatitis herpetiformis: quantitative measurements of dermoepidermal alterations. Arch Dermatol 118: 950, 1982.
5. Fine JD, Breathnach SM, and Katz SI: KF-1 monoclonal antibody defines a specific basement membrane antigenic defect in dystrophic forms of epidermolysis bullosa. J Invest Dermatol 80: 314, 1983.
6. Hintner H, Fine JD, Neises GR, Steinart P, and Lawley TJ: Monoclonal antibody reacting with "profilaggrin". Clin Res 31: 264A, 1983.
7. Fine JD: Epidermolysis bullosa: variability of expression of cicatricial pemphigoid, bullous pemphigoid, and epidermolysis bullosa acquisita antigens. Presented at the annual meeting of American Dermatologic Society for Allergy and Immunology, Boston, Sept. 1984.
- 8a & b. Fine JD: Peanut agglutinin defines an epidermal cell membrane defect in skin from patients with epidermolysis bullosa simplex. Clin Res 32: 911A, 1984, and 33: 298A, 1985.
- 9a & b. Fine JD, Redmar DA, and Goodman AL: Reappearance of seven basement membrane antigens in primate skin following split-thickness wound induction. Clin Res 33: 636A, 1985, and J Invest Dermatol 84: 353, 1985.
10. O'Sullivan FX, Fine JD, Koopman WJ, and Gay S: Immunohistological studies on normal appearing skin in the MRL mouse. Clin Res 33: 510A, 1985.
11. Fine JD, Gay S: Detection of a new ubiquitous non-collagenous component of basement membrane by monoclonal antibody technique. Clin Res 34: 265A, 1986.
- 12 a-c. Gay S, Fine JD, Storer JS: Autoantibodies to extracellular matrix components in epidermolysis bullosa and other bullous disorders. Clin Res 34: 266A & 751A, 1986, and J Invest Dermatol 86: 477, 1986.
13. Glawson JH, Denys FR, Gay RE, Fine JD, Gay S: Immunoelectron x-ray microprobe analysis of basement membrane using defined monoclonal antibodies against type IV collagen. Fed Proc 45: 464, 1986.
14. Gay S, Fine JD, Gay RE, Glawson J: Human basement membrane specificity of a monoclonal antibody against human type IV collagen. Clin Res 34: 416A, 1986.
- 15 a & b. Fine JD, Gay S: Characterization of a new ubiquitous non-collagenous component of basement membrane as defined by monoclonal antibody technique. J Invest Dermatol 86: 475, 1986, and Clin Res 34: 749A, 1986.
16. Fine JD, Stewart B, Austin R: Epidermolysis bullosa blister fluid and human skin organ culture: an unreliable in vitro model for the disease. J Invest Dermatol 87: 139, 1986.
17. Fine JD: Altered antigenicity of the dermoepidermal junction in epidermolysis bullosa. For Workshop on "Prenatal diagnosis of inherited skin diseases", 17th World Congress of Dermatology, Berlin, 5/87, Abstract Volume 1, pp. 283-284.
- 18 a & b. Fine JD, Couchman J, Holbrook K: Chondroitin-6-sulfate-containing proteoglycan as a new component of human skin dermoepidermal junction. Clin Res 35: 86A, 1986, and J Invest Dermatol 88: 488, 1987.
19. Fine JD, O'Sullivan FX, Spiers EM, Koopman WJ, Gay S: Immunopathology of the MRL mouse and response to ultraviolet B irradiation. Fed Proc 46: 1375, 1987.



20. Jester J, Fine J-D: Identification of a new human-specific keratinocyte cytoplasmic particulate antigen by a monoclonal antibody. J Invest Dermatol 88: 496, 1987.
21. Fine JD, Tying S: Epidermolysis bullosa acquisita and intra-lamina lucida blister formation: possible role of leukocytes. Clin Res 35: 387A, 1987.
22. Tamayo L, Fine JD, Sanchez Gomez MT: Epidermolisis bullosas. Diagnostico por ultraestructura y anticuerpos monoclonales. Presented at the XI Ibero-latino-americano Congress of Dermatology, Madrid, Spain, May 1987.
23. Fine JD, Johnson L: Efficacy of topical parfenac (bufexamac) in epidermolysis bullosa simplex: results of a double blind placebo- controlled crossover trial. J Clin Pharmacol 27: 723, 1987.
24. Fine JD, Johnson L: Efficacy of systemic phenytoin in the treatment of junctional epidermolysis bullosa (JEB). J Clin Pharmacol 27: 723, 1987.
25. Fine JD, Couchman J: 19-DEJ-1: a unique human-specific basement membrane antigen identified by monoclonal antibody technique. J Cell Biol 105(4): 41a, 1987.
26. Fine JD, Horiguchi Y, Couchman J: Detection and partial characterization of a basement membrane antigen having unique tissue distribution and ultrastructural localization within human skin. Clin Res 36: 84A, 1988.
27. Fine JD, Couchman J: 19-DEJ-1 monoclonal antibody defines a new skin basement membrane antigenic defect in junctional and dystrophic epidermolysis bullosa. Clin Res 36: 84A, 1988.
28. Wright JT, Capps J, Johnson LB, Fine JD: Oral and ultrastructural dental manifestations of epidermolysis bullosa. J Dental Res 67: 249, 1988.
29. Tying SK, Fine JD: Natural killer cell activity is depressed in patients with junctional and dystrophic epidermolysis bullosa but not in patients with the simplex form. Clin Res 36: 86A, 1988.
30. Hawkins HK, Eady RAJ, Levy ML, Carpenter RJ, Hejtmancik JF, Holbrook KA, Fine JD: Prenatal diagnosis of dominant dystrophic epidermolysis bullosa. Clin Res 36: 58A, 1988.
31. Fine JD, Couchman J: 19-DEJ-1, a hemidesmosome-anchoring filament complex-associated monoclonal antibody, defines a new skin basement membrane antigenic defect in junctional and dystrophic epidermolysis bullosa. Clin Res 36: 375A, 1988.
32. Fine JD, Horiguchi Y, Couchman J: Detection and partial characterization of a hemidesmosome-anchoring filament complex-associated antigen present within human skin. J Invest Dermatol 90: 558, 1988.
33. Fine JD, Couchman J: Chondroitin-6-sulfate proteoglycan but not heparan sulfate proteoglycan is abnormally expressed in skin basement membrane from patients with dystrophic epidermolysis bullosa. J Invest Dermatol 90: 558, 1988.
34. Horiguchi Y, Couchman J, Ljubimov AV, Vesiliev JM, Yamasaki H, Fine JD: Organ specificity, ontogeny, and ultrastructural localization of the core protein of heparan sulfate proteoglycan, a component of human skin basement membrane. J Invest Dermatol 90: 570, 1988.
35. Horiguchi Y, Fine JD: Basement membrane expression, keratinocyte growth, and collagen redistribution within a human artificial skin equivalent. Clin Res 36: 376A, 1988.
36. Rusenko KW, Gammon WR, Fine J-D, Briggaman RA: The carboxyl-terminal domain of type VII collagen is present in recessive dystrophic epidermolysis bullosa. J Invest Dermatol 90: 604, 1988.
37. Tying SK, Fine JD: Depressed cell mediated immunity in patients with severe forms of inherited epidermolysis bullosa. Clin Res 36: 380A, 1988.
38. Chopra V, Tying S, Vaidya S, Johnson L, Fine JD: Depressed cell mediated immunity in patients with severe inherited forms of epidermolysis bullosa. J Leukocyte Biology 44: 262, 1988.
39. Fine JD, Couchman J, Ljubimov AV, Vasiliev JM, Yamasaki H, Horiguchi Y: Chondroitin 6-sulfate and heparan sulfate containing proteoglycans: immunohistochemical characterization and isolation from human skin. J Histochem Cytochem 36 (7A): 864, 1988.

40. Couchman JR, [Fine JD](#): Proteoglycan involvement in dystrophic epidermolysis bullosa. Presented at the 18th annual meeting of the Southern Connective Tissue Society, Birmingham, AL, April 27-29, 1988.
41. Kletter G, Evans OB, Lee JA, [Fine JD](#), Bock HGO: An association between congenital muscular dystrophy and epidermolysis bullosa simplex. Presented at the 11th summer meeting of the Southern Genetics Group, Navarre Beach, FL, July 28-30, 1988.
42. Finley WH, Lindsey JR Jr, [Fine JD](#), Dixon GA: Pimery erythralgia (erythromelalgia). Presented at the 11th summer meeting of the Southern Genetics Group, Navarre Beach, FL, July 28-30, 1988.
43. Finley WH, Lindsey JR Jr, [Fine JD](#), Dixon DA: Familial primary erythralgia (erythromelalgia). [Am J Hum Gen](#) 43 (3): A49, 1988.
44. Vaidya S, Tying S, Johnson L, [Fine JD](#): HLA-DR & DQ association in recessive dystrophic epidermolysis bullosa. Presented at the 14th annual meeting of the American Society for Histocompatibility and Immunogenetics.
45. [Fine JD](#), Bynum K, Mihocik A, Krell J, Miller EJ: Further characterization of LDA-1, a ubiquitous component of human basement membranes. [J Cell Biol](#) 107: 591a, 1988.
46. Horiguchi Y, [Fine JD](#), Couchman JR, Ljubimov AV, Yamasaki H: Entactin: ultrastructural localization of a basement membrane glycoprotein in mouse skin. [Clin Res](#) 37: 79A, 1988.
47. [Fine JD](#), Bynum K, Mihocik A, Krell J, Miller EJ: Biochemical characterization of LDA-1, a ubiquitous human basement membrane component. [Clin Res](#) 37: 78A, 1988.
48. Wright J, Capps J, [Fine JD](#), Johnson L: Dental caries in the different epidermolysis bullosa diseases. [J Dental Res](#) 68: 416, 1989.
49. Couchman JR, McCarthy KJ, [Fine JD](#): Characterization of a basement membrane-specific chondroitin sulfate proteoglycan in rat skin. [Clin Res](#) 37: 78A, 1988.
50. Horiguchi Y, Abrahamson D, [Fine JD](#): Epitope mapping of the laminin molecule in murine skin basement membrane zone: demonstration of differences in ultrastructural localization. [J Invest Dermatol](#) 92: 447A, 1989.
51. [Fine JD](#), Bynum K, Mihocik A, Krell J, Miller EJ: LDA-1: biochemical characterization of a ubiquitous human skin basement membrane component. [J Invest Dermatol](#) 92: 428A, 1989.
52. Tying SK, Vaidya S, Johnson L, [Fine JD](#): HLA class II antigens associated with recessive dystrophic epidermolysis bullosa. [J Invest Dermatol](#) 92: 535A, 1989.
53. [Fine JD](#), Horiguchi Y, Madri JA: Ultrastructural localization of AB2 type V collagen in human skin basement membrane and its expression in epidermolysis bullosa. [Clin Res](#) 37 (2): 358A, 1989.
54. Mihocik A, Miller EJ, Horiguchi Y, [Fine JD](#): Distribution of lentactin: a novel component of the extracellular matrix. Presented at the 19th annual meeting of the Southern Connective Tissue Society, Tampa, FL, March 30, 1989.
55. Lin AN, Stern RS, Caldwell-Brown D, Carter DM, and collaborators: Phenytoin for recessive dystrophic epidermolysis bullosa. [J Invest Dermatol](#) 92: 472, 1989.
56. Horiguchi Y, [Fine JD](#), Engvall E: Localization of laminin epitopes in human fetal skin: evidence for selective redistribution as a function of developmental age. [J Cell Biol](#) 109 (4): 44a, 1989.
57. [Fine JD](#): GB3 antigen is an accurate marker of only the Herlitz subset of junctional epidermolysis bullosa. [Clin Res](#) 38 (1): 72A, 1990.
58. [Fine JD](#), Horiguchi Y, Stein DH, Esterly NB, Leigh IM: Intraepidermal type VII collagen: defective cytoplasmic processing of a major skin basement membrane protein in a subset of patients with dystrophic epidermolysis bullosa. [Clin Res](#) 38 (1): 72A, 1990.
59. Horiguchi Y, [Fine JD](#), Couchman JR, Engvall E: Expression of heparan sulfate proteoglycan and laminin in developing human fetal skin basement membrane: differences in ultrastructural localization are dependent on developmental age. [Clin Res](#) 38 (1): 73A, 1990, and [J Invest Dermatol](#) 94: 536, 1990.

60. Couchman JR, Horiguchi Y, McCarthy KJ, [Fine JD](#): Immunohistochemical localization of a basement membrane chondroitin sulfate proteoglycan by core protein-specific monoclonal antibodies. [Clin Res](#) 38 (1): 72A, 1990.
61. [Fine JD](#): 19-DEJ-1, a monoclonal antibody to the hemidesmosome-anchoring filament complex, is the only reliable immunohistochemical probe for all forms of junctional epidermolysis bullosa. [Clin Res](#) 38 (2): 420A, 1990.
62. Schofield OMV, [Fine JD](#), Pisani A, Heagerty AHM, Ortonne JP, Eady RAJ: GB3 monoclonal antibody for the diagnosis of junctional epidermolysis bullosa: results of a multicentre study. [J Invest Dermatol](#) 95: 487, 1990.
63. [Fine JD](#), Bynum K, Brysk M: LDA-1 and 19-DEJ-1 antigens: further characterization of two novel skin basement membrane components. [Clin Res](#) 38 (4): 930A, 1990, 39 (2): 561A, 1991, and [J Invest Dermatol](#) 96: 536A, 1991.
64. Chan LS, [Fine JD](#), Briggaman RA, Woodley DT, Hammerberg C, Drugge R, Cooper KD: Identification of a novel autoimmune bullous dermatosis and a novel 105-kD basement membrane protein that is defective in dystrophic epidermolysis bullosa. [Clin Res](#) 39: 477A, 1991.
65. [Fine J-D](#), Johnson LB, Leigh IM, Briggaman RA: Intracytoplasmic retention of type VII collagen and dominant dystrophic epidermolysis bullosa: ultrastructural evidence of reversal of defect following cessation of or marked improvement in disease activity. [Clin Res](#) 39: 323A, 1991.
66. Horiguchi Y, [Fine J-D](#), Leigh IM, Imamura S: Involvement of lamina densa malformation in amyloidogenesis of primary cutaneous amyloidosis. [Clin Res](#) 39: 526A, 1991.
67. [Fine J-D](#), Quaranta V, Horiguchi Y, Yoshiki T, Ueda M, Briggaman RA: Relative Expression of Four Hemidesmosome-Associated Proteins in Junctional Epidermolysis Bullosa, a Disease of Epithelial Dysadhesion With Known Abnormal Hemidesmosomes. [J Cell Biol](#) 115 (3): 134a, 1991.
68. [Fine J-D](#): Immunofluorescence antigenic mapping and monoclonal antibody studies in inherited epidermolysis bullosa: summary of 8 years' experience in 483 consecutive cases. Book of Abstracts, 18th World Congress of Dermatology, New York, 6/92.
69. Heise ER, Mangum K, [Fine J-D](#), Briggaman RA, Gammon WR: Non-DR2 related risk factors in type VII autoimmunity. [J Invest Dermatol](#) 98: 587, 1992.
70. [Fine J-D](#), Quaranta V, Daniels A, Gammon R, Briggaman RA:  $\alpha 6 \beta 4$  integrin, a hemidesmosome-associated glycoprotein, is normally expressed in junctional epidermolysis bullosa. [J Invest Dermatol](#) 98: 572, 1992.
71. Chan LS, [Fine J-D](#), Hammerberg, C, Cooper KD: Failure of a novel 105-kD lower lamina lucida protein to incorporate into the skin basement membrane of patients with dystrophic epidermolysis bullosa. [J Invest Dermatol](#) 98: 588, 1992.
72. Wright JT, [Fine J-D](#), Johnson LB: Enamel hypoplasia in the different types of hereditary epidermolysis bullosa. [J Dental Res](#) 72: 536, 1992.
73. Horiguchi Y, Leigh IM, [Fine J-D](#), Yoshiki T, Maruguchi T, Suzuki S, Imamura S: Ultrastructure and antigen expression of keratinocytes cultured on type I collagen sponge-matrigel equivalent. Proceedings of the 3rd China-Japan Joint Meeting of Dermatology, 117, 1992.
74. Wright JT, [Fine JD](#), Johnson LB: Dental caries risk in hereditary epidermolysis bullosa. [J Dental Res](#) (1993; in press).
75. Zeng L, Daniels A, Cronic D, [Fine JD](#): 19-DEJ-1, a component of anchoring filaments undetectable in junctional epidermolysis bullosa skin, is synthesized by normal human keratinocytes. [J Invest Dermatol](#) 100: 505, 1993.
76. [Fine JD](#), Daniels A, Zeng L: Comparative analysis of the sensitivity and specificity of 19-DEJ-1 and GB3 monoclonal antibodies for diagnosis and subclassification of junctional epidermolysis bullosa subsets. [J Invest Dermatol](#) 100: 531, 1993.
77. [Fine JD](#), Daniels A, Zeng L, Cronic D, Briggaman R: Comparative analysis of the sensitivity and specificity of anchoring fibrils and type VII collagen for diagnosis and subclassification of dystrophic epidermolysis bullosa subsets. [J Invest Dermatol](#) 100: 532, 1993.

78. Zeng L, Daniels A, [Fine JD](#): 19-DEJ-1, an antigenic component of anchoring filaments undetectable in junctional epidermolysis bullosa skin, may be biochemically related to kalinin. [Molecular Biology of the Cell](#) 4 (Suppl): 69a, 1993.
79. Suchindran CM, Tien H, Johnson LB, [Fine JD](#): Statistical models for subclassification of epidermolysis bullosa. [Clin Res](#) 41 (4): 743A. 1993.
80. [Fine JD](#), Zeng L, Daniels A, Riddelle K: Uncein (19-DEJ-1) and kalinin, two protein components of skin anchoring filaments, have markedly different expression by human keratinocyte monolayers in vitro. [Clin Res](#) 41 (4): 743A. 1993.
81. Zeng L, Daniels A, Cronce D, [Fine JD](#): A polyclonal antibody (Li-1) to isolated uncein (19-DEJ-1), a component of the human anchoring filament, reveals a ubiquitous distribution of antigen within skin basement membranes. [Clin Res](#) 41 (4): 743A. 1993.
82. Horiguchi Y, Ueda M, Matsuyoshi N, Takahashi K, [Fine J-D](#), Imamura S: Keratinocytes and fibroblasts produce a novel anchoring fibril-associated protein. [J Invest Dermatol](#) 101: 392A, 1993.
83. Zeng K, Daniels A, Riddelle K, [Fine JD](#): Uncein, an anchoring filament component, is biochemically similar to kalinin but differs markedly in its in vitro expression by normal human keratinocyte monolayers. [J Invest Dermatol](#) 102: 535, 1994.
84. Zeng K, Daniels A, Riddelle K, [Fine JD](#): Uncein, but not kalinin, is abnormally expressed in cultured non-Herlitz junctional epidermolysis bullosa (JEB) keratinocytes. [J Invest Dermatol](#) 102: 558, 1994.
85. Zeng K, Daniels A, Riddelle K, Cronce D, Briggaman R, [Fine JD](#): Polyclonal antibodies to subunits of uncein, an anchoring filament protein, reveal striking differences in tissue and ultrastructural localization. [J Invest Dermatol](#) 102: 549, 1994.
86. Riddelle K, Zeng L, Daniels A, [Fine JD](#): Co-incubation of monoclonal antibodies against uncein or nicein does not affect the adhesion of normal human keratinocytes in culture. [J Invest Dermatol](#) 102: 620, 1994.
87. Riddelle K, Zeng L, Daniels A, [Fine JD](#): Relationship of uncein and nicein to cytoskeletal components as analyzed by confocal microscopy of normal and transformed keratinocytes. [J Invest Dermatol](#) 102: 620, 1994.
88. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: The National Epidermolysis Bullosa Registry - basic demographic characteristics of a prospective multicenter project. [J Invest Dermatol](#) 102: 618, 1994, and 103: 846, 1994.
89. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Classification and regression tree (CART) statistical technique for diagnosis of major types of inherited epidermolysis bullosa (EB) - a split sample analysis of the National EB Registry dataset. [J Invest Dermatol](#) 102: 618, 1994, and 103: 846, 1994.
90. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: The National Epidermolysis Bullosa (EB) Registry - risk of prematurity, frequency of pregnancy complications, and effect of maternal and paternal ages on the development of each of the major EB types. [J Invest Dermatol](#) 102: 618, 1994, and 103: 846, 1994.
91. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: The National Epidermolysis Bullosa (EB) Registry - differences in frequencies of selected gastrointestinal manifestations and cancers across major disease types. [J Invest Dermatol](#) 102: 618, 1994, and 103: 846, 1994.
92. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: The National Epidermolysis Bullosa (EB) Registry - differences in frequencies of extracutaneous involvement across major disease types. [J Invest Dermatol](#) 102: 558, 1994, and 103: 846, 1994.
93. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Skin cancer and inherited epidermolysis bullosa (EB)

- analysis of the National EB Registry cohort by disease type and subtype. *J Invest Dermatol* 102: 541, 1994, and 103: 846, 1994.
94. Fine JD, Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: The National Epidermolysis Bullosa Registry - assessment of interobserver variability by sensitivity and specificity analysis of two major clinical parameters. *J Invest Dermatol* 102: 618, 1994, and 103: 847, 1994.
  95. Fine JD, Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: The diversity of cutaneous and extracutaneous findings in epidermolysis bullosa (EB) simplex is a function of severity of disease subtype. *J Invest Dermatol* 102: 571, 1994, and 103: 847, 1994.
  96. Fine JD, Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: The protean nature of cutaneous manifestations in inherited epidermolysis bullosa - analysis of the frequency of findings by major subtype of disease in a large, well-defined cohort of patients. *J Invest Dermatol* 102: 573, 1994, and 103: 847, 1994.
  97. Fine JD, Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: The National Epidermolysis Bullosa Registry - differences by major and minor EB type in age of onset, age and means of diagnosis, and presence or absence of significant associated extracutaneous disease. *J Invest Dermatol* 102: 571, 1994, and 103: 847, 1994.
  98. Fine JD, Suchindran C, Tien H, Johnson LB, Moshell A: Statistical classification models for inherited epidermolysis bullosa (EB) - comparison of the influence of different clinical variables on sensitivity and specificity. *J Invest Dermatol* 102: 618, 1994, and 103: 847, 1994.
  99. Johnson LB, Fine JD, Tien HC, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: The National Epidermolysis Bullosa Registry (NEBR) - definition of a rare group of diseases and selected outcomes via longitudinal observation. (presented at the 1994 national meeting of the American Public Health Association).
  100. Johnson LB, Fine JD, Tien HC, Suchindran C, Moshell A: Classification and regression tree analysis (CART) - identification of factors responsible in limiting predictability of all major disease subsets in the National Epidermolysis Bullosa Registry (NEBR). (presented at the 1994 national meeting of the American Public Health Association).
  101. Lin AN, Smith LT, Fine JD: Inverse dystrophic epidermolysis bullosa: report of two cases with further correlation between immunofluorescence studies and electron microscopy *J Invest Dermatol* 103: 851, 1994.
  102. Zeng K, Daniels A, Riddelle K, Fine JD: Uncsein, a cell membrane-associated anchoring filament component, is biochemically similar to kalinin but differs markedly in its in vitro expression by normal and non-Herlitz junctional (JEB) keratinocyte monolayers. *J Invest Dermatol* 103: 855, 1994.
  103. Zeng K, Daniels A, Riddelle K, Cronce D, Briggaman R, Fine JD: Two polyclonal antibodies to the anchoring filament protein, uncsein, reveal differences in subunit recognition and in tissue and ultrastructural localization. *J Invest Dermatol* 103: 855, 1994.
  104. Fine JD, Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Risk of esophageal webbing or stenosis in inherited epidermolysis bullosa (EB): assessment by lifetable analysis technique. *J Invest Dermatol* 103: 847, 1994.
  105. Fine JD, Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Pseudosyndactyly (mitten deformities) and inherited epidermolysis bullosa (EB): time to onset in major EB subsets as determined by lifetable analysis technique. *J Invest Dermatol* 103: 847, 1994.
  106. Fine JD, Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Tracheolaryngeal stenosis and inherited epidermolysis bullosa (EB): determination of differences in time of onset, as assessed by lifetable analysis technique. *J Invest Dermatol* 103: 847, 1994.

107. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Risk of skin cancers and inherited epidermolysis bullosa (EB) – Determination of differences across major EB Subtypes, as assessed by lifetable analysis technique. [J Invest Dermatol](#) 103: 847, 1994.
108. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Brock L, Moshell A: Risk of premature death and inherited epidermolysis bullosa (EB) – assessment by lifetable analysis across major EB types and subtypes of patients within one regional center of the National Epidermolysis Bullosa Registry (NEBR). [J Invest Dermatol](#) 103: 847, 1994.
109. Riddelle K, Daniels A, Zeng L, [Fine JD](#): Confocal microscopic analysis of the distribution of two skin basement membrane components. [J Invest Dermatol](#) 103: 852, 1994.
110. Wright JT, Hall KI, Deaton T, [Fine J-D](#): The enamel ultrastructure of teeth in hereditary epidermolysis bullosa. [J Invest Dermatol](#) 103: 854, 1994.
111. Wright JT, Hall KI, Deaton T, [Fine J-D](#): The mineral composition of tooth enamel in hereditary epidermolysis bullosa. [J Invest Dermatol](#) 103: 854, 1994.
112. Shimizu H, Hattori N, Hirone T, [Fine J-D](#), Bruckner-Tuderman L, Tanaka T, Nishikawa T: Expression of various epidermal basement membrane associated antigens in 36 Japanese patients with epidermolysis bullosa. [J Dermatological Science](#) (1994; in press) (for the meeting of the Japanese Society for Investigative Dermatology, Osaka, Japan).
113. Riddelle K, Zeng L, Daniels A, Marinkovich MP, [Fine J-D](#): Confocal microscopical comparison of two anchoring filament components, uncein and laminin-5, to cytoskeletal constituents in normal human keratinocytes. [Molecular Biology of the Cell](#) 5 (Suppl): 55a, 1994.
114. Zeng L, Daniels A, Riddelle K, Pittelkow MR, [Fine J-D](#): Uncein, an anchoring filament component, differs from kalinin biochemically and in its in vitro expression by normal and junctional epidermolysis bullosa (JEB) human keratinocyte monolayers. [Molecular Biology of the Cell](#) 5 (Suppl): 305a, 1994.
115. Zeng L, Riddelle K, Daniels A, Bloom K, [Fine J-D](#): Molecular cloning of uncein, an anchoring filament protein abnormally expressed in all junctional epidermolysis bullosa (JEB) skin - partial sequencing of a completely novel gene. [J Invest Dermatol](#) 104 (4): 582, 1995.
116. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Squamous cell carcinomas, basal cell carcinomas, and malignant melanomas in inherited epidermolysis bullosa (EB): cumulative risk, as assessed by lifetable analysis of the National EB Registry dataset. [J Invest Dermatol](#) 104 (4): 620, 1995.
117. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Premature death and inherited epidermolysis bullosa (EB): cumulative risk, as assessed by lifetable analysis of the National EB Registry dataset. [J Invest Dermatol](#) 104 (4): 621, 1995.
118. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Esophageal stenosis and inherited epidermolysis bullosa (EB): cumulative risk, as assessed by lifetable analysis of the National EB Registry dataset. [J Invest Dermatol](#) 104 (4): 621, 1995.
119. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Pseudosyndactyly and inherited epidermolysis bullosa (EB): cumulative risk, as determined by lifetable analysis of the National EB Registry dataset. [J Invest Dermatol](#) 104 (4): 667, 1995.
120. [Fine JD](#), Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Squamous cell carcinoma (SCC) and recessive dystrophic EB of the Hallopeau-Siemens (RDEB-HS) subtype: analysis of the influence of the extracutaneous disease activity, in vivo expression of type VII collagen, and race on both presence and number of tumors, and risk of subsequent death. [J Invest Dermatol](#) 104 (4): 621, 1995.

121. Fine JD, Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Socioeconomic considerations of inherited epidermolysis bullosa (EB). J Invest Dermatol 104 (4): 621, 1995.
122. Fine JD, Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Tracheolaryngeal stenosis and inherited epidermolysis bullosa (EB): cumulative risk, as assessed by lifetable analysis. J Invest Dermatol 104 (4): 621, 1995.
123. Wright JT, Hall KI, Deaton T, Fine J-D: Structural and compositional alteration of tooth enamel in hereditary epidermolysis bullosa. Presented at the 12/95 meeting on Chemistry and Biology of Mineralized Tissue.
124. Fine JD, Johnson LB, Tien H, Suchindran C, Brock L, Bauer EA, Carter DM, Sybert V, Lin A, J Krueger, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Estimated incidence and prevalence, and lifetable projection of years of life lost by each major epidermolysis bullosa (EB) subtype. J Invest Dermatol 106: 893, 1996.
125. Johnson LB, Murphy HM, Fine J-D, Smith JL: Skin cancer prevention and the public health nurse. Presented at the annual meeting of the American Public Health Association, November 1996.
126. Fine JD, Johnson LB, Tien H, Suchindran C, Bauer EA, Carter DM, Sybert V, Lin A, Caldwell-Brown D, Stern R, McGuire J, Spencer A, Gibbons S, Brust M, Nall L, Moshell A: Cumulative risk of major clinical outcomes, including cancer and death, in inherited epidermolysis bullosa (EB). Presented at the annual meeting of the American Public Health Association, November 1996.
127. Olivry T, Poujade-Delverdiere A, Dunston SL, Fine J-D, Ortonne J-P: Defective expression of collagen XVII (BPAG2, BP180) in canine familial non-lethal junctional epidermolysis bullosa. Presented at the annual meeting of the American College of Veterinary Dermatology, April 1996.
128. Olivry T, Fine JD, Dunston S, Chasse D, Pascal A, Monteiro-Riviere N: A novel canine autoimmune subepidermal bullous dermatosis resembling epidermolysis bullosa acquisita in humans. Presented at the 3rd World Congress of Veterinary Dermatology, Edinburgh, Scotland, held in September 1996.
129. Shimizu H, Sata M, Ban M, Kitajima Y, Ishizaki J, Harada T, Bruckner-Tuderman L, Fine J-D, Kon A, Uitto J, Nishikawa T: Characteristic immunohistochemical and ultrastructural features of Kindler's syndrome distinguishing it from dystrophic epidermolysis bullosa. J Dermatol Science, 1996.
130. Fine J-D, Moshell A: The National Epidermolysis Bullosa Registry: a longitudinal epidemiologic project which can facilitate the performance of basic skin research. Presented on behalf of the Symposium on EB, Jefferson Medical College, Philadelphia, PA, held in April 1996.
131. Fine J-D: Lessons from clinical epidemiology and the National EB Registry. Presented at the annual meeting of the American Dermatological Association, held at Sea Island, GA, October 25-29, 1997.
132. Johnson LB, Murphy H, Fine J-D, Smith JL: A distance learning continuing education program on skin cancer prevention and early detection. Presented at the symposium on Integrating Public Health Programs for Cancer Control, held in Atlanta, GA, on Sept. 2-5, 1997.
133. Fine J-D: For whom is it done? The National Epidermolysis Bullosa Registry in the USA. Presented at an international symposium on blistering diseases (Satellite Symposium on Hereditary and Acquired Bullous Dermatoses of the International Investigative Dermatology 1998 Meeting) held in Salzburg, Austria, on May 2-3, 1998.
134. Fine J-D: Inherited epidermolysis bullosa: selected outcomes and a revised classification system. Ped Dermatol (part of the proceedings of the annual meeting of the Society for Pediatric Dermatology, held at Traverse City, MI, in August 1999). Pediatr Dermatol 17(1): 81-82, 2000.
135. Fine J-D, Johnson LB, Suchindran C, Weiner M: Inherited EB and the cost of health care in the United States: the National EB Registry experience. (presented at the international symposium, EB 2000, held in London, UK, in September 2000).
136. Fine J-D, Johnson LB, Suchindran C, Weiner M: Inherited EB and the American health care system: patient perceptions and relative utilization. (presented at the international symposium, EB 2000, held in London, UK, in September 2000).

137. [Fine J-D](#), Johnson LB, Suchindran C, Weiner M: Inherited EB: differences in children by EB type and subtype in activities of daily living (ADL) and disease-associated pain. (presented at the international symposium, EB 2000, held in London, UK, in September 2000).
138. [Fine J-D](#), Johnson LB, Suchindran C, Weiner M: Impact of inherited EB on parental interpersonal relationships, marital status, and family size. (presented at the international symposium, EB 2000, held in London, UK, in September 2000).
139. [Fine J-D](#), Johnson LB, Suchindran C, Weiner M: Parenteral guilt, blame, anxiety, self-image, depression, and religious beliefs: impact of having a child affected with inherited EB. (presented at the international symposium, EB 2000, held in London, UK, in September 2000).
140. [Fine J-D](#), Johnson LB, Suchindran C, Weiner M: Inherited EB in childhood: impact on the family unit and relationships with others. (presented at the international symposium, EB 2000, held in London, UK, in September 2000).
141. [Fine J-D](#): The National Epidermolysis Bullosa Registry (NEBR): Past, present, and future. (presented at the international symposium, EB 2000, held in London, UK, in September 2000).
142. [Fine J-D](#), Weiner M, Stein A, Suchindran C, Johnson LB: Systemic isotretinoin and recessive dystrophic epidermolysis bullosa (RDEB): results of a Phase I clinical trial. [J Invest Dermatol](#) 117: 543, 2001.
143. [Fine J-D](#), Johnson LB, Weiner M, Stein A, Suchindran C: Basal cell carcinomas and malignant melanomas in inherited epidermolysis bullosa (EB) within the United States: experience of the National EB Registry (NEBR), 1986-2000. [J Invest Dermatol](#) 117: 493, 2001.
144. [Fine J-D](#), Johnson LB, Weiner M, Stein A, Suchindran C: Frequency and cumulative risk of cutaneous squamous cell carcinomas in inherited epidermolysis bullosa within the United States: experience of the National EB Registry (NEBR), 1986-2000. [J Invest Dermatol](#) 117: 492, 2001.
145. [Fine J-D](#), Johnson LB, Stein A, Suchindran C, Zhou J, Weiner M: Inherited epidermolysis bullosa and the American health care system: differences in EB type in the utilization of inpatient and outpatient facilities and of specialists, and patient-parental satisfaction. [J Invest Dermatol](#) 117: 540, 2001.
146. [Fine J-D](#), Johnson LB, Stein A, Suchindran C, Chuan HT, Weiner M: The cost of health care for inherited epidermolysis bullosa in the United States: differences in relative coverage for inpatient and outpatient services, and overall estimates of yearly expenses. [J Invest Dermatol](#) 117: 540, 2001.
147. [Fine J-D](#), Johnson LB, Stein A, Suchindran C, Morgan M, Weiner M: Activities of daily living (ADL) and disease-associated pain in children with inherited epidermolysis bullosa (EB). [J Invest Dermatol](#) 117: 541, 2001.
148. [Fine J-D](#), Johnson LB, Stein A, Suchindran C, Beasley K, Weiner M: Inherited epidermolysis bullosa: impact of an affected child on parental interpersonal relationships, marital status, and the decision to have additional children. [J Invest Dermatol](#) 117: 541, 2001.
149. [Fine J-D](#), Johnson LB, Stein A, Kim HJ, Suchindran C, Amused J, Weiner M: Inherited epidermolysis bullosa: impact of an affected child on parental feelings of guilt, blame, anxiety, self-image, and depression, religious beliefs, and ability to cope, and the risk of suicide in affected adults. [J Invest Dermatol](#) 117: 541, 2001.
150. [Fine J-D](#), Johnson LB, Stein A, Guest P, Suchindran C, Weiner M: Impact of an affected child with epidermolysis bullosa (EB) on the functionality of the family unit and the ways in which parents are regarded by others within their own communities. [J Invest Dermatol](#) 117: 541, 2001.
151. [Fine J-D](#), Johnson LB, Weiner M, Stein A, Suchindran C: Cumulative and conditional probabilities of death from squamous cell carcinoma (SCC) in recessive dystrophic epidermolysis bullosa (RDEB): experience of the National EB Registry (NEBR), 1886-2000. [J Invest Dermatol](#) 117: 492, 2001.
152. [Fine J-D](#), Johnson LB, Weiner M, Stein A, Brock L, Suchindran C: Risk of death in inherited epidermolysis bullosa (EB): cumulative and conditional probabilities, based on the experience of the National EB Registry (NEBR), 1986-2000. [J Invest Dermatol](#) 117: 540, 2001.



153. Keane F, Fine J-D, Weiner M, Stein A, McGrath JA, Eady R: Osteopenia and osteoporosis in recessive dystrophic epidermolysis bullosa (RDEB): results of DEXA scans in 42 consecutively studied patients within the United Kingdom and United States. J Invest Dermatol 117: 543, 2001.
154. Keane F, Fine J-D, Pillay E, Stein A, McGrath JA, Eady RAJ: Osteopenia and osteopenia in recessive dystrophic epidermolysis bullosa. (presented at the annual meeting of the British Association of Dermatologists, Cardiff, Wales, July 2001).
155. Martinez-Mir1 A, O'Shannessy R, Lui J, Weiner MS, Gordon D, Ott J, Gilliam TC, Fine J-D, Christiano AM: The gene for epidermolysis bullosa simplex superficialis maps to chromosome 3p21. J Invest Dermatol 117: 516, 2001.
156. Fine JD, Johnson LB, Weiner M, Cash S, DeVries DT, DeLeoz J, Suchindran C: What have statistics taught us about EB? (accepted for presentation at the 20th World Congress of Dermatology, Paris, France, July 2002).
157. DeVries DT, Fine J-D: Inadequate coverage of daily costs in patients with severe forms of epidermolysis bullosa: results of the National Epidermolysis Bullosa Registry. (presented at the First Doris Duke Clinical Research Fellowship Conference, St. Louis, MO, June 2002).
158. Fine JD, Johnson LB, Weiner M: Genitourinary complications of inherited EB. (presented at "Clinical Management of Children and Adults with Epidermolysis Bullosa: A Multidisciplinary International Symposium", London, England, October 2003).
159. Fine JD, Johnson LB, Weiner M: Major outcomes and inherited EB: overall and cause-specific cumulative risks of death. (presented at "Clinical Management of Children and Adults with Epidermolysis Bullosa: A Multidisciplinary International Symposium", London, England, October 2003).
160. Fine JD, Johnson LB, Weiner M: Cancer and inherited EB. (presented at "Clinical Management of Children and Adults with Epidermolysis Bullosa: A Multidisciplinary International Symposium", London, England, October 2003).
161. Fine JD: Structural integrity of the skin: clinicopathological and molecular correlates. (presented at the Winter 2004 meeting of the North Carolina Dermatological Association, Pinehurst, NC, January 2004).
162. Rubin AI, Moran K, Fine J-D, Wargon O, Murrell DF: Urethral meatal stenosis in junctional epidermolysis bullosa. A rare complication effectively treated with a novel and simple modality. Australasian J Dermatol (presented, Spring 2006).
163. Fine J-D: Epidermolysis bullosa: a genetic disease of altered cell adhesion and wound healing, and the possible clinical utility of topically applied thymosin  $\beta$ 4. (presented at the 1st International Symposium on Thymosins in Health and Disease, Washington, DC, 3/07).

#### E. Books

1. Fine J-D (Editor): *Bullous Diseases*. In Topics in Clinical Dermatology series, Igaku-Shoin Medical Publishers, New York / Tokyo, 1993, 218 pp.
2. Fine J-D (Editor-in-Chief), Bauer EA, McGuire J, and Moshell A: *Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry*. Johns Hopkins University Press, Baltimore, May 1999, 520 pp.
3. Fine J-D and Hinter H, editors, *Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy* Springer Verlag GmbH, Wien New York, 2008 (in press)

#### F. Theses

1. Fine J-D: *Comparative analysis of the accuracy of four laboratory techniques for the diagnosis and subclassification of inherited epidermolysis bullosa: a study based on 575 consecutive cases initially examined by specialized immunohistochemistry from 1983 to 1992*. Master's thesis in partial fulfillment of the requirements for the degree of Master of Public Health, Department of Epidemiology, University of North Carolina at Chapel, December 1992.

#### G. Other Scholarly and Professional Works

1. Fine J-D, Arndt KA: Seborrheic dermatitis. Patient information pamphlet prepared for and distributed by the American Academy of Dermatology, 1984.
2. Fine J-D, Lee Charles: Dr. Cutis, a working prototype of an interactive multimedia computer program for the teaching of basic dermatologic principles using the case study approach, 1996 (utilized by UNC second year medical students, as part of their course requirements, 1996 - 2001).
3. Fine J-D, McGrath K: General guidelines to the routine management and care of inherited EB. Patient and physician oriented pamphlet prepared for and distributed by DebRA of America (to include electronic version via Internet web site), 2000.
4. Fine J-D: Internet web site for the National EB Registry, containing selected published data, University of North Carolina, 2000.
5. Co-author of "Living with EB" (an informational pamphlet produced by NIAMS for distribution to patients, lay audiences, and physicians), August 2002.
6. Fine J-D: Papulosquamous diseases. In Pocket Diagnosis in Internal Medicine (ed. by Mitchell MC Jr., for the Palm Pilot), PocketMedicine.com Inc., 2003.
7. Fine JD: Epidermolysis bullosa. BMJ Publishing Group BMJ In-Practice Web Site (2008). [a peer reviewed project by the Br Med J, linked with Epocrates drug database] [also listed under Review Articles]

## Research Funding

### Principal Investigator: Jo-David Fine

1. Active:

RegeneRx Biopharmaceuticals. "Clinical trial on wound healing in epidermolysis bullosa with thymosin-beta-4". 11/05 - present. 2% effort. Total costs = \$50,000.

2. Submitted or pending applications: none

3. Applications in preparation: none

4. Completed grants:

Dystrophic Epidermolysis Bullosa Research Association of America. "DEBRA nurse clinician / educator". 6/05 - 5/07. Total yearly costs = \$6,358.

NIH (NIAMS), NO1 AR72233. "National Epidermolysis Bullosa Registry". 5/1/97 - 4/30/02. 25% effort. Total costs = \$2,173,012.

NIH (NIAMS), K24 AR02098 (Midcareer Investigator Award for Patient-Oriented Research). "Genotype correlates of inherited EB". 5/1/99 - 4/31/04. 50% effort. Direct costs (Yr 1) = \$88,522. (Priority Score = 124) [terminated at request of P.I. on 8/1/02, due to career change]

Engelhorn Foundation for Rare Diseases (Luxembourg). "International Epidermolysis Bullosa Registry". 4/1/01 - 3/31/02. Total costs = \$30,000.

Roche Laboratories. "Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa with Accutane". 7/1/99 - 6/30/04. Medication to be provided for 200 participants for 5 years of clinical testing.) [terminated at request of P.I. on 8/1/02]

Dystrophic Epidermolysis Bullosa Research Association of America. "DEBRA Clinical Research Fellowship". 7/1/00 - 6/30/02. Total costs (yearly) = \$40,000.

Novartis Pharmaceuticals Corporation. "Unrestricted educational donation to the Medical Foundation of North Carolina for research on epidermolysis bullosa". 9/1/01. Total costs = \$50,000.

Food and Drug Administration (Orphan Diseases Program). FD-R-001796-01. "Accutane, cancer chemoprevention, and dystrophic EB" (Phase I trial). 10/1/00 - 9/30/02. 5% effort. Total costs = \$144,723 (one year, with no-cost extension for 2nd year.) [terminated at request of P.I. on 4/26/02]

Burroughs Wellcome Fund. "Burroughs Wellcome Fund Research Travel Grant -- Relationship of genotype to phenotypes and the risk of major outcomes in junctional and dystrophic epidermolysis bullosa". 9/1/00 - 2/28/01. Total costs = \$14,500.

NIH (NIAMS), NO1 AR22200. "National Epidermolysis Bullosa Registry - Clinical Coordinating Center". 5/1/92 - 4/30/97. Total costs = \$1,217,357.

NIH (NIAMS), NO1 AR22201. "National Epidermolysis Bullosa Registry - Clinical Site". 5/1/92 - 4/30/97. Total costs = \$952,705.

NIH (NIAMS), NO1 AM62271. "National Epidermolysis Bullosa Registry - Clinical Site". 9/24/86 - 9/23/91. Total costs = \$452,859.

NIH (NIAMS), 1 R13 AR42649. "International Symposium on Epidermolysis Bullosa". 4/25/94 - 4/26/94. Total direct costs = \$11,000.

NIH (NIAMS), 2 RO1 AR34861-06. "Skin basement membrane zone and epidermolysis bullosa". 7/1/91 - 6/30/94. Total costs = \$494,323.

NIH (NIAMS), 1 R23 AM34861-03 (New Investigator Research Award). "Monoclonal antibodies to skin basement membrane zone". 8/1/85 - 7/31/88. Total costs = \$144,999.

NIH (NIAMS), 5 RO1 AR36629-03. "Physiologic biomatrices and epidermolysis bullosa". 9/30/85 - 8/31/88. Total costs = \$377,500.

Veterans Administration Medical Research Service, Merit Review Award. "Characterization of basement membrane structural antigens in skin". 10/1/85 - 9/30/88. Total costs = \$109,396.

Veterans Administration Medical Research Service (RAGS Proposal). "Characterization of basement membrane zone antigens in human skin". 10/1/84 - 9/30/85. Total costs = \$23,300.

American Cyanamid Company. "Viprostol male pattern alopecia clinical trial". 1/1/87 - 9/1/88. Total costs = \$92,240.

Dreyfus Medical Foundation. "A study of the efficacy of dilantin in children with junctional epidermolysis bullosa". 6/1/85 - 5/31/86. Total costs = \$1,850.

Dermatology Foundation. "Determination of differences in cell membrane glycoproteins in skin from patients with epidermolysis bullosa simplex as previously defined by abnormal peanut agglutinin lectin binding". 1/1/85 - 12/31/95. Total costs = \$5,000.

5. Unfunded proposals (recent):

Food and Drug Administration (Orphan Diseases Program). "Accutane, cancer chemoprevention, and dystrophic EB" (Phase 2/3 trial). 10/1/01 - 9/30/04. 25% effort. Direct costs (Yr 1, \$295,000; total, \$872,003), Total costs (Yr 1, \$429,225; total, \$1,268,764).

NIH (NIAMS), RFP BAA-0002 (submitted 6/9/00). "Cutaneous Lymphoma Registry". 10% effort. 9/1/00 - 8/31/05. Total costs = \$2,339,476.

NIH (NIAMS), RFP BAA-0002 (submitted 6/9/00). "Pemphigus Registry" (LA Diaz, P.I.). 10% effort. 9/1/00 - 8/31/05. Annual costs (Yr 1 only) = \$381,759

Principal Investigator: Other

1. Active: none
2. Pending: none
3. Completed:

Doris Duke Foundation. "Clinical Research Fellowship Program" (Paul Watkins, P.I.; J-D Fine, mentor). 7/1/01 - 6/30/02. Total costs (to mentor, excluding stipend to fellow) = \$5,000.

Centers for Disease Control and Prevention / Environmental Health. "Pfiesteria-related illness surveillance and prevention" (Christine Moe, P.I.; J-D Fine, consultant, 5% effort, one year only). 3/1/98 - 2/28/01. Total costs = \$981,960.

Centers for Disease Control and Prevention / Health Promotion and Disease Prevention Center (U48/CCU 409660). "Development and evaluation of a skin cancer education program for public health nurses" (Lorraine Johnson, P.I.; J-D Fine, Co-Investigator, 2% effort). 9/30/94 - 9/30/98. Total costs = \$304,381.